Author: "Urrutia, A." / Topic: business.industry - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Urrutia, A."' showing total 1,640 results

Start Over Author "Urrutia, A." Topic business.industry

1,640 results on '"Urrutia, A."'

1. Efficacy of whole-body cryotherapy in the treatment of chronic low back pain: Quasi-experimental study

Author: Krystle Urrutia-García, Oscar Salas-Fraire, Karina Salas-Longoria, Nancy P. Guevara-Neri, Oscar Armando Martínez-Gutiérrez, Juan Antonio Rivera-Pérez, and Rodolfo Morales-Avalos
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Whole body cryotherapy, Cryotherapy, Chronic low back pain, Oswestry Disability Index, Informed consent, Rating scale, Quasi experimental study, Physical therapy, Medicine, Orthopedics and Sports Medicine, Surgery, In patient, business
Abstract: Single arm, quasi-experimental study design.To describe the effects of whole-body cryotherapy on pain, disability, and serum inflammatory markers in patients with chronic low back pain.A quasi-experimental trial was performed on adult patients between 18 and 65 years with chronic low back pain. After obtaining informed consent, participants underwent 20 sessions of whole-body cryotherapy (at -160 °C) during a 5-week time span. Patient reported pain and disability measures (Pain Numerical Rating Scale [PNRS], Oswestry Disability Index [OSI], and Roland Morris Questionnaire [RMQ]) were obtained at each of the twenty sessions. Blood samples were obtained to analyze serum inflammatory markers at baseline, 10th and 20th session.Forty-one participants were included in the study. A significant decrease was observed between the initial and final PNRS, ODI, and RMQ scores (p 0.001). A significant reduction in the PNRS was found after 4 sessions of whole-body cryotherapy (p 0.001). We observed decreasing values of pro-inflammatory serum marker IL-2 (p = 0.046) and a significant increase in the anti-inflammatory serum marker IL-10 (p = 0.003). No adverse events were reported during the study.Whole-body cryotherapy is an effective therapy for pain and disability treatment in chronic low back pain. It also produces changes in serum markers of inflammation, decreasing pro-inflammatory markers and increasing anti-inflammatory markers.
Published: 2023
Full Text: View/download PDF

2. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author: Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
Subjects: Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract: Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
Published: 2021
Full Text: View/download PDF

3. Influencia del inicio precoz del tratamiento conservador en la evolución del paciente pediátrico con vejiga neuropática

Author: M.J. Martínez Urrutia, R. Lobato Romera, S. Rivas Vila, P. López Pereira, and L Burgos Lucena
Subjects: medicine.medical_specialty, Urinary continence, medicine.drug_class, business.industry, Urology, Reflux, Renal function, Retrospective cohort study, urologic and male genital diseases, medicine.disease, female genital diseases and pregnancy complications, Surgery, Overactive bladder, Bladder augmentation, medicine, Anticholinergic, Intermittent catheterisation, business
Abstract: Background Clean intermittent catheterization (CIC) and anticholinergic drugs are the mainstay treatment for neuropathic bladder (NB). However, there is not consensus about the time therapy should be started in pediatric patients. Aim To analyze the impact of early start (first year of life) of CIC and anticholinergic treatment on long-term renal and bladder function. Our hypothesis is that those children who start conservative treatment in the first year of life have better outcome in terms of bladder and renal function and less need of surgical procedures, compared to those who started treatment later in life. Patients and method Retrospective study of pediatric patients with NB treated in our hospital (1995-2005) dividing them for comparison in two groups: group 1 started treatment in the first year of life and group 2 between 1 and 5 years old. Collected data included: date of CIC and anticholinergic initiation, presence of VUR or UHN, renal function, UTIs, renal scars, bladder behavior, surgery and urinary continence. Results Sixty-one patients were included, 25 in group 1 and 36 in group 2. Initially vesico-ureteral reflux (VUR) and overactive bladders were more frequent in group 2. In group 1 one overactive bladder changed to low compliant and in group 2, one normal bladder and 4 overactive bladders changed. At the end of follow-up there were 11 low compliant bladders in group 1 and 17 in group 2. However, in group 1, only 2 patients required bladder augmentation (BA) while in group 2, 12 patients needed it. At the end of the study only 2 patients in group 2 had slight renal insufficiency. Conclusions Patients who started conservative treatment in the first year of life have better long-term outcome in terms of UTI, renal scars and surgical procedures. Even if they initially had low compliant bladders, these patients require less BA.
Published: 2022
Full Text: View/download PDF

4. Phase angle is a better indicator of nutritional status than body mass index in patients on hemodialysis

Author: Daniela Meza-Guillén, Carlos A. López-Lozano, Anel V. Barbarín-Vázquez, Jesemil Navarro-Rodríguez, Renato Parra-Michel, Ma. L. Cervantes-Villalobos, Jorge F. Topete-Reyes, Juan Gabriel Juárez-Rojas, Aida Medina-Urrutia, Margarita Torres-Tamayo, Sandra L. López-Báez, and H. Leonardo Pazarín-Villaseñor
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Phase angle, medicine, Cardiology, In patient, Nutritional status, General Medicine, Hemodialysis, business, Body mass index
Published: 2023
Full Text: View/download PDF

5. Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model

Author: Jong-In Park, Michael A. Zimmerman, Angela Mathison, David F. Stowe, Catherine Hagen, Joohyun Kim, Amadou K.S. Camara, Gwen Lomberk, Ju Seog Lee, Meiying Yang, Brent T. Boettcher, Joseph E McGraw, Jyotsna Mishra, Johnny C. Hong, Raul Urrutia, Muhammed Ali, Woo Young Shin, and Harvey J. Woehlck
Subjects: Necrosis, business.industry, medicine.medical_treatment, Cellular homeostasis, Liver transplantation, medicine.disease, Cytoplasm organization, Andrology, Transplantation, medicine.anatomical_structure, Apoptosis, Hepatocyte, medicine, Surgery, medicine.symptom, business, Reperfusion injury
Abstract: Objective We sought to investigate the biological effects of pre-reperfusion treatments of the liver after warm and cold ischemic injuries in a porcine donation after circulatory death (DCD) model. Summary of background data DCD represents a severe form of liver ischemia and reperfusion injury that has a profound impact on graft function after liver transplantation. Methods Twenty donor pig livers underwent 60 minutes of in situ warm ischemia after circulatory arrest and 120 minutes of cold static preservation prior to simulated transplantation using an ex vivo perfusion machine. Four reperfusion treatments were compared: Control-Normothermic (N), Control-Subnormothermic (S), regulated hepatic reperfusion (RHR)-N, and RHR-S (n = 5 each). The biochemical, metabolic, and transcriptomic profiles, as well as mitochondrial function were analyzed. Results Compared to the other groups, RHR-S treated group showed significantly lower post-reperfusion aspartate aminotransferase levels in the reperfusion effluent and histologic findings of hepatocyte viability and lesser degree of congestion and necrosis. RHR-S resulted in a significantly higher mitochondrial respiratory control index and calcium retention capacity. Transcriptomic profile analysis showed that treatment with RHR-S activated cell survival and viability, cellular homeostasis as well as other biological functions involved in tissue repair such as cytoskeleton or cytoplasm organization, cell migration, transcription, and microtubule dynamics. Furthermore, RHR-S inhibited organismal death, morbidity and mortality, necrosis, and apoptosis. Conclusion Subnormothermic RHR mitigates IRI and preserves hepatic mitochondrial function after warm and cold hepatic ischemia. This organ resuscitative therapy may also trigger the activation of protective genes against IRI. Subnormothermic RHR has potential applicability to clinical liver transplantation.
Published: 2023

6. Combination of olanzapine with bispectral index guided anesthesia to prevent postoperative delirium in elderly patients undergoing major gastrointestinal elective surgery: a randomized, double-blind, placebo-controlled study protocol

Author: Raquel Costa, Osama Alzobi, Diego Arbaje, Veronica Hernandez Leon, Flavia Tarcha, Jannis Müller, Eleonora Boschetti Grutzmacher, Ibnouf Sulieman, Eman Youssif, Diego Noya Rabelo, Pedro Hilton de Andrade Filho, Catherine Skinner, Maria Belen Cubria, Juliana Tepedino Martins Alves, Muhammad Haseeb, Brahim Khouri Lopez, Aline Marcadenti, Denise Saretta Schwartz, Salim Al-Busaidi, Diego Daniel Garcia Choza, Denisse Castro, Annette García Delgado, Gabriela Casais, Victor Batistella, Francisca Urrutia Goldsack, Arturo Tamayo, and Moyses Cohen
Subjects: Olanzapine, medicine.medical_specialty, business.industry, medicine.medical_treatment, Placebo-controlled study, Placebo, Anesthesia, Bispectral index, medicine, Delirium, Neurosurgery, Elective surgery, medicine.symptom, Antipsychotic, business, medicine.drug
Abstract: Introduction: Postoperative delirium (POD) is an important complication of major surgery in elderly patients. It increases morbidity and mortality, hospital stay, and total healthcare costs. Since no treatment has proven effective once POD is established, prevention is key. Evidence exists that bispectral index guided anesthesia (BIS-GA) and antipsychotics may independently reduce incidence of POD, but the efficacy of combining these preventive strategies is unknown. Objective: To compare the combination of olanzapine + BIS-GA with BIS-GA alone for prevention of POD in elderly patients undergoing major elective surgery.Methods: We propose a Phase II, multi-center, randomized, double-blind, parallel, placebo-controlled trial. The study arms will be BIS-GA + two doses of olanzapine 5mg given pre and postoperatively compared with BIS-GA + placebo in patients ≥65 years hospitalized for major elective surgery. Exclusion criteria include cardiac- and neurosurgery, dementia history, concurrent antipsychotic, anticholinergic, or sedative-hypnotic use, olanzapine allergy, delirium at hospital admission, cognitive impairment and inability to be interviewed. The primary outcome is incidence of POD diagnosed by DSM-V criteria and assessed by the Confusion Assessment Method (CAM) scale. Secondary outcomes include delirium severity, rescue therapy use, length of hospital stay and incidence of adverse events.Discussion: There is an increasing need for trials that advance knowledge in prophylactic methods to prevent delirium. By combining two preventive methods, we expect to decrease the incidence of POD, which will result in decreased morbidity, mortality, and total healthcare costs.
Published: 2021
Full Text: View/download PDF

7. The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions

Author: Julian E. Garcia, Melissa A. Daubert, Craig R. Lee, Matthew Shane Loop, Ian R. Mulrenin, Muluneh M. Fashe, and Rachel Peragallo Urrutia
Subjects: medicine.medical_specialty, Nifedipine, medicine.drug_class, Toxicology, Article, Pharmacokinetics, Pregnancy, Humans, Medicine, Labetalol, Dosing, Antihypertensive drug, Intensive care medicine, Antihypertensive Agents, Pharmacology, business.industry, Hypertension, Pregnancy-Induced, General Medicine, medicine.disease, Bioavailability, Pharmaceutical Preparations, Gestation, Female, business, medicine.drug
Abstract: INTRODUCTION: Hypertensive disorders of pregnancy (HDP) are rising in prevalence, and increase risk of adverse maternal and fetal outcomes. Physiologic changes occur during pregnancy that alter drug pharmacokinetics. However, antihypertensive drugs lack pregnancy-specific dosing recommendations due to critical knowledge gaps surrounding the extent of gestational changes in antihypertensive drug pharmacokinetics and underlying mechanisms. AREAS COVERED: This review (1) summarizes currently recommended medications and dosing strategies for non-emergent HDP treatment, (2) reviews and synthesizes existing literature identified via a comprehensive Pubmed search evaluating gestational changes in the maternal pharmacokinetics of commonly prescribed HDP drugs (notably labetalol and nifedipine), and (3) offers insight into the metabolism and clearance mechanisms underlying altered HDP drug pharmacokinetics during pregnancy. Remaining knowledge gaps and future research directions are summarized. EXPERT OPINION: A series of small pharmacokinetic studies illustrate higher oral clearance of labetalol and nifedipine during pregnancy. Pharmacokinetic modeling and preclinical studies suggest these effects are likely due to pregnancy-associated increases in hepatic UGT1A1- and CYP3A4-mediated first-pass metabolism and lower bioavailability. Accordingly, higher and/or more frequent doses may be needed to lower blood pressure during pregnancy. Future research is needed to address various evidence gaps and inform the development of more precise antihypertensive drug dosing strategies.
Published: 2021
Full Text: View/download PDF

8. Precision medicine in trauma: a transformational frontier in patient care, education, and research

Author: Gwen Lomberk, Christina Georgeades, Nathaniel James Carpenter, Katheryn Hope Wilkinson, Raul Urrutia, Christopher S. Davis, and Emily Lin
Subjects: Epigenomics, medicine.medical_specialty, Genomics, Review Article, Critical Care and Intensive Care Medicine, Intervention (counseling), medicine, Humans, Orthopedics and Sports Medicine, Intensive care medicine, Cause of death, business.industry, Precision medicine, Trauma surgery, Personalized medicine, United States, Pharmacogenomics, Emergency Medicine, Surgery, Patient Care, business
Abstract: Purpose Trauma is the leading cause of death before the age of 45 in the United States. Precision medicine (PM) is the most advanced scientific form of medical practice and seeks to gather data from the genome, environmental interactions, and lifestyles. Relating to trauma, PM promises to significantly advance our understanding of the factors that contribute to the physiologic response to injury. Methods We review the status of PM-driven trauma care. Semantic-based methods were used to gather data on genetic/epigenetic variability previously linked to the principal causes of trauma-related outcomes. Data were curated to include human investigations involving genomics/epigenomics with clinical relevance identifiable early after injury. Results Most studies relevant to genomic/epigenomic differences in trauma are specific to traumatic brain injury and injury-related sepsis. Genomic/epigenomic differences rarely encompass other relevant factors, such as coagulability and pharmacogenomics. Few studies describe clinical use of genomics/epigenomics for therapeutic intervention in trauma care, and even fewer attempt to incorporate real-time genomic/epigenomic information to precisely guide clinical decision-making. Conclusion Considering that genomics/epigenomics, environmental exposures, and lifestyles are most likely to be of significant medical relevance in advancing the field of trauma, the lack of application of concepts and methodologies from PM to trauma education, research, practice, and community wellness is underwhelming. We suggest that significant effort be given to incorporate the tools of what is becoming the “new medicine”.
Published: 2021

9. La experiencia de implementar una historia clínica electrónica en siete centros en menos de un año

Author: Ariel L. Fernández, Miguel Angel Urrutia, Walter Maestri, Mercedes Salomé Agostinelli, and María P. Arias López
Subjects: Process management, Computer science, business.industry, Process (engineering), Health care, Digital transformation, Electronic medical record, Organizational culture, General Medicine, Quality of care, business, Multidisciplinary team
Abstract: Introducción: Extensa evidencia publicada sugiere que la implementación de una historia clínica electrónica (HCE) tiene potencial de mejorar la calidad de la atención, disminuyendo errores médicos causados por falta de coordinación, comunicación, pérdida de información, etc. Las dificultades encontradas en el proceso de informatización varían según la infraestructura local. Nuestro objetivo es describir un modelo de implementación exitoso de una HCE en un medio con un grado de informatización institucional y regional heterogéneo que pueda resultar útil en similares escenarios. Métodos: Descripción de una implementación llevada a cabo por un equipo multidisciplinario, utilizando un proceso estandarizado y un modelo sustentado en compromiso y apoyo de los referentes institucionales, comunicación efectiva del proyecto a todos los actores, planificación del entrenamiento y monitoreo de las etapas predefinidas. Resultados: El modelo de implementación descripto permitió poner en producción una HCE en menos de un año en siete centros (ambulatorios e internación). Más de 2000 usuarios recibieron entrenamiento personalizado en su ámbito de trabajo, focalizado en sus necesidades. El éxito de la implementación radicó en alcanzar el compromiso del nivel ejecutivo y de los líderes locales sumado a una adecuada planificación y a la adaptación del modelo a la cultura organizacional. Disponer de un equipo de implementación para brindar a los usuarios soporte en tiempo y forma y adecuado a sus necesidades fue también clave para el éxito del proceso. Conclusiones: La implementación de una HCE usando un modelo estandarizado permitió disminuir la variabilidad del proceso, mejorar los resultados finales y dejar la estructura preparada para continuar ampliando la informatización de los centros.
Published: 2021
Full Text: View/download PDF

10. Antidepressants and Black Box Warning: Duty to Inform or Unintended Consequence of Cautious Response

Author: Hanife Akal, Ainsley Backman, Sadiq Naveed, Victoria Urrutia, Muhammad Zeshan, and Salma Malik
Subjects: Black box (phreaking), Psychiatry and Mental health, business.industry, media_common.quotation_subject, Medicine, Advertising, business, Duty, media_common
Abstract: Suicide is a global health problem. According to the World Health Organization, more than 700,000 people a year die because of suicide. About 90% of suicides in the United States are associated with a psychiatric illness, with major depressive disorder (MDD) accounting for 50% of these cases. Although antidepressants are the preferred choice for the treatment of MDD with or without suicidal ideations, they can cause worsening of suicidal ideations in some cases. In October 2004, the US Food and Drug Administration (FDA) directed manufacturers of all antidepressants to add a “black box” warning regarding possible worsening suicidal thoughts and behaviors in patients younger than age 18 years. In 2006, the FDA extended this warning to young adults up to age 24 years. Since then, there has been significant discussion regarding the warning, its merits and impact, and the implications on the use of antidepressants for the effective management of MDD. This article reviews the historical background of the black box warning, existing evidence, and recommendations on effectively communicating with children/adolescents and their caregivers. [ Psychiatr Ann . 2021;51(10):467–472.]
Published: 2021
Full Text: View/download PDF

11. Routine Biomarkers for the Severity of COVID-19 Pneumonia May Present Differently in Kidney Transplant Recipients

Author: Javier Paul-Martinez, Ricardo Lauzurica, Elena Burgos, Omar Taco, Judit Cacho, Marina Urrutia-Jou, Fredzzia Graterol, María Molina, Inés Perezpayá, Javier Juega, and Laura Cañas
Subjects: Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Lymphocyte, Gastroenterology, Article, Interquartile range, Internal medicine, medicine, Humans, Aged, Transplantation, biology, business.industry, Hazard ratio, COVID-19, Pneumonia, Middle Aged, medicine.disease, Kidney Transplantation, Confidence interval, Ferritin, medicine.anatomical_structure, biology.protein, Etiology, Female, Surgery, business, Biomarkers
Abstract: Background The treatment of coronavirus disease 2019 (COVID-19) is based on the patient's clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in kidney transplant (KT) patients with COVID-19 pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non–SARS-CoV-2 etiologies is unknown. The aim of this study was to compare the clinical presentation and inflammatory parameters at admission of KT patients with COVID-19 pneumonia and those with non–COVID-19 pneumonia over the same period. Methods Biomarkers were measured and compared between KT patients with COVID-19 pneumonia (n = 57) and non-COVID-19 pneumonia (n = 20) from March 2020 to March 2021. Results Both groups showed comparable demographics. The KT patients with COVID-19 had fewer neutrophils (6824 ± 5000 vs 8969 ± 4206; P = .09) than the non-COVID group, although there was no significant difference in the lymphocyte count. Non–COVID-19 pneumonia was associated with higher d -dimer (median, 921 [interquartile range (IQR), 495-1680] vs median, 2215 [IQR, 879-3934]; P = 0.09) and interleukin-6 (median, 35 [IQR, 20-128] vs median, 222 [IQR, 38-500]; P = 0.006) levels. The ferritin level was higher in the COVID-19 group (median, 809 [IQR, 442-1,330] vs median, 377 [IQR, 276-885]; P = 0.008). In multivariable analysis, only d -dimer (hazard ratio [HR], 1; 95% confidence interval [CI],1-1.002; P = .02) and ferritin (HR, 1; 95% CI, 0.9-0.9; P = .02) increase the statistic signification. Conclusion COVID-19 pneumonia in KT patients shows a different presentation of inflammatory biomarkers than other non-COVID pneumonias. It could be useful to identify KT patients with COVID-19. More detailed studies are necessary to understand the presentation of biomarkers in KT with COVID-19.
Published: 2021
Full Text: View/download PDF

12. Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes

Author: Priyathama Vellanki, David W. Lam, Katherine R. Tuttle, Rodolfo J. Galindo, Maria A. Urrutia, Karla Walkiria Zamudio-Coronado, Limin Peng, Georgia Davis, Maya Fayfman, Citlalli Perez-Guzman, Radica Z. Alicic, Guillermo E. Umpierrez, Alexandra Migdal, Saumeth Cardona, and Francisco J. Pasquel
Subjects: Blood Glucose, Insulin degludec, medicine.medical_specialty, Randomization, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Insulin Glargine, Type 2 diabetes, Article, law.invention, Endocrinology, Randomized controlled trial, law, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Humans, Hypoglycemic Agents, Prospective Studies, Glycated Hemoglobin, Inpatients, business.industry, Insulin, medicine.disease, Hospitals, Insulin, Long-Acting, Regimen, Diabetes Mellitus, Type 2, Basal (medicine), business
Abstract: AIMS: Limited data exists about the use of insulin degludec in the hospital. This multicentre, non-inferiority, open-label, prospective randomised trial compared the safety and efficacy of insulin degludec-U100 and glargine-U100 for the management of hospitalized patients with type 2 diabetes. METHODS: A total of 180 general medicine and surgery patients with an admission blood glucose (BG) between 7·8 – 22·2 mmol/L, treated with oral agents or insulin prior to hospitalization were randomly allocated (1:1) to a basal bolus regimen using degludec (n=92) or glargine (n=88), as basal and aspart before meals. Insulin dose was adjusted daily to a target BG between 3·9 – 10·0 mmol/L. The primary end point was difference in the mean hospital daily BG between groups. RESULTS: Overall, the randomization BG was 12·2 ± 2·9 mmol/L and HbA1c 84 mmol/mol (9·8±2·0%). There were no differences in mean daily BG (10·0±2·1 vs. 10·0±2·5 mmol/L, p=0·9), proportion of BG in target range (54·5± 29% vs. 55·3 ± 28%, p=0·85), basal insulin (29·6 ± 13 vs 30·4 ± 18 units/day, p=0·85), length of stay (median (IQR): 6·7 (4·7–10·5) vs. 7·5 (4·7–11·6) days, p=0·61), hospital complications (23% vs. 23%, p=0·95) between treatment groups. There were no differences in the proportion of patients with BG
Published: 2021
Full Text: View/download PDF

13. Organizational learning culture in industry 4.0: relationships with work engagement and turnover intention

Author: Giovana Urrutia Pereira, Manoela Ziebell de Oliveira, and Wagner de Lara Machado
Subjects: Organizational Behavior and Human Resource Management, Industry 4.0, business.industry, Work engagement, Organizational learning, Turnover intention, Digital transformation, Information technology, Public relations, business, Psychology, Adaptation (computer science), Period (music)
Abstract: The period of digital transformation that we are experiencing, called Industry 4.0, has marked a series of changes in the way we relate as a society, requiring constant adaptation and new knowledge...
Published: 2021
Full Text: View/download PDF

14. Aplasia congénita unilateral del cartílago alar

Author: F Alfredo Urrutia, C Daniel Cantero, M Jaime Osorio, and D Angélica Suazo
Subjects: business.industry, Medicine, General Medicine, Anatomy, Aplasia, business, medicine.disease
Published: 2021
Full Text: View/download PDF

15. Systemic Adverse Reactions to Psychotropic Medications: What Do We Need to Know?

Author: Lovejit Kaur, Salma Malik, Sadiq Naveed, Victoria Urrutia, and Justin Marshall
Subjects: Psychiatry and Mental health, medicine.medical_specialty, business.industry, Need to know, Medicine, business, Intensive care medicine
Abstract: This article focuses on potential systemic adverse reactions secondary to use of psychotropic agents. Clinicians, at times, have to manage these relatively uncommon systemic side effects. If not managed in a timely manner, these side effects could contribute to morbidity and mortality. This article reviews the prevalence, neurobiological underpinning, course, diagnosis, management, and prognosis of serotonin syndrome, neuroleptic malignant syndrome, lithium toxicity, antiepileptic hypersensitivity reactions (DRESS syndrome and Stevens-Johnson syndrome), and discontinuation syndromes. Prescribers need to be cognizant and should be knowledgeable in understanding and managing these potential systemic side effects. [ Psychiatr Ann . 2021;51(9):421–426.]
Published: 2021
Full Text: View/download PDF

16. Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology

Author: José María Ignacio, Isabel Urrutia, Vicente Plaza, Marina Blanco-Aparicio, and Aurelio Arnedillo
Subjects: Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, mites, Consensus, medicine.medical_treatment, Disease, sublingual, immune system diseases, Pulmonary Medicine, medicine, Animals, Humans, Immunology and Allergy, In patient, Sublingual immunotherapy, Antigens, Dermatophagoides, Asthma, House dust mite, Sublingual Immunotherapy, biology, business.industry, Pyroglyphidae, Public Health, Environmental and Occupational Health, Allergic asthma, Immunotherapy, asthma, medicine.disease, biology.organism_classification, Dermatology, respiratory tract diseases, subcutaneous, immunotherapy, business
Abstract: Introduction: Many patients sensitized to mites remain symptomatic and uncontrolled despite traditional treatment. Sublingual immunotherapy (SLIT) has demonstrated to reduce the symptoms of allergic rhinitis, the need for additional drug treatments, and to reduce the number of moderate and severe exacerbations in patients with allergic asthma caused by mites that had not been adequately controlled. Areas covered: After reviewing the most recent literature, a scientific committee composed by five pneumologists experts in asthma proposed 41 items that addressed the diagnosis of allergic asthma caused by mites, the role of house dust mite (HDM) SLIT tablet in the therapeutic plan and in the control of the disease, and the profile of patients with asthma candidates for this therapy. Through a modified Delphi method, the items were send to 106 pneumologists involved in asthma to be agreed. Expert opinion: The high degree of consensus reached by the panel of pneumologists shows the importance of HDM SLIT tablet in the treatment of allergic asthma caused by mites, particularly taking into account that they barely use this therapy because until now they did not have a registered treatment with solid evidence of efficacy and safety.
Published: 2021
Full Text: View/download PDF

17. An independent inter- and intra-observer agreement assessment of the Eno classification of sacroiliac joint degeneration

Author: Pablo Cikutovic, Marcelo Valacco, Gaston Camino-Willhuber, Julio Urrutia, Matias Borensztein, Nelson Astur, and Osvaldo Velan
Subjects: Scoring system, Computed tomography, 03 medical and health sciences, 0302 clinical medicine, Cohen's kappa, Ankylosis, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Observer Variation, Sacroiliac joint, 030222 orthopedics, Radiological and Ultrasound Technology, medicine.diagnostic_test, business.industry, Reproducibility of Results, Sacroiliac Joint, General Medicine, medicine.disease, Intra observer, Clinical Practice, medicine.anatomical_structure, Tomography, X-Ray Computed, business, Nuclear medicine, 030217 neurology & neurosurgery, Kappa
Abstract: Background Recently, a scoring system to grade sacroiliac joint (SIJ) degeneration using computed tomography (CT) scans was described. No independent evaluation has determined the inter- and intra-observer agreement using this scheme. Purpose To perform an independent inter- and intra-observer agreement assessment using the Eno classification and determining gas in the SIJ. Material and Methods We studied 64 patients aged ≥60 years who were evaluated with abdominal and pelvic computed tomography scans. Six physicians (three orthopaedic spine surgeons and three musculoskeletal radiologists) assessed axial images to grade SIJ degeneration into grade 0 (normal), grade 1 (mild degeneration), grade 2 (significant degeneration), and grade 3 (ankylosis). We also evaluated the agreement assessing the presence of gas in the SIJ. After a four-week interval, all cases were presented in a random sequence for repeat assessment. We determined the agreement using the kappa (κ) or weighted kappa coefficient (wκ). Results The inter-observer agreement was moderate (wκ = 0.50 [0.44–0.56]), without differences among surgeons (wκ = 0.53 [0.45–0.61]) and radiologists (wκ = 0.49 [0.42–0.57]). The agreement evaluating the presence of gas was also moderate (κ = 0.45 [0.35–0.54]), but radiologists obtained better agreement (κ = 0.61 [0.48–0.72]) than surgeons (κ = 0.29 [0.18–0.39]). The intra-observer agreement using the classification was substantial (wκ = 0.79 [0.76–0.82]), without differences comparing surgeons (wκ = 0.75 [0.70–0.80]) and radiologists (wκ = 0.83 [0.79–0.87]). The intra-rater agreement evaluating gas was substantial (κ = 0.77 [0.72–0.82]), without differences between surgeons (κ = 0.71 [0.63–0.78]) and radiologists (κ = 0.84 [0.78–0.90]). Conclusion Given the only moderate agreement obtained using the Eno classification, it does not seem adequate to be used in clinical practice or in research.
Published: 2021
Full Text: View/download PDF

18. Correlation between 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in patients with Parkinson’s disease: a pilot study

Author: Julieta E. Arena, Leandro Urrutia, Germán Falasco, Magdalena Ponce de Leon, Silvia Vazquez, Malco Rossi, and Marcelo Merello
Subjects: 0301 basic medicine, Movement disorders, Parkinson's disease, 99mtc trodat 1, R895-920, Positron-emission tomography/methods, Dihydroxyphenylalanine/analogs & derivatives, Correlation, Medical physics. Medical radiology. Nuclear medicine, 03 medical and health sciences, 0302 clinical medicine, 18f fdopa, medicine, Radiology, Nuclear Medicine and imaging, In patient, Fluorodopa, Tomography, emission-computed, single-photon/methods, medicine.diagnostic_test, business.industry, medicine.disease, 030104 developmental biology, Tropanes/pharmacokinetics, Parkinson disease/diagnostic imaging, medicine.symptom, Nuclear medicine, business, Parkinsonian disorders/diagnostic imaging, 030217 neurology & neurosurgery, Emission computed tomography
Abstract: Objective: To determine whether technetium-99m-labeled tropane derivative single-photon emission computed tomography (99mTc-TRODAT-1 SPECT) provides results comparable to those of the less widely available, less accessible tool fluorine-18-labeled fluorodopa positron-emission tomography (18F-FDOPA PET) in the setting of a movement disorders clinic. Materials and Methods: In this prospective pilot study, eight subjects with a clinical diagnosis of Parkinson’s disease were randomly selected from among patients under treatment at a movement disorders clinic and submitted to 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET. The results were read by two experienced observers, and a semiquantitative analysis was performed. Results: The visual and semiquantitative analyses were concordant for all studies, showing that radiotracer uptake in the contralateral striatum on the most affected side was lower when 99mTc-TRODAT-1 SPECT was employed. The semiquantitative analysis demonstrated a significant correlation between 18F-FDOPA PET and 99mTc-TRODAT-1 SPECT (r = 0.73; p < 0.01). Conclusion: It appears that 99mTc-TRODAT-1 SPECT is a valid option for the study of dopaminergic function in a clinical setting.
Published: 2021
Full Text: View/download PDF

19. Dust from the Sahara to the American Continent: Health impacts

Author: Herberto José Chong-Neto, Marilyn Urrutia-Pereira, Patrícia Latour Staffeld, Giovanni Viegi, Luciana V. Rizzo, and Dirceu Solé
Subjects: Pulmonary and Respiratory Medicine, Pollution, Mediterranean climate, Saharan Air Layer, medicine.medical_specialty, Amazon rainforest, business.industry, media_common.quotation_subject, Public health, Immunology, General Medicine, Mineral dust, complex mixtures, Atmosphere, medicine, Immunology and Allergy, Physical geography, business, Air mass, media_common
Abstract: The Saharan Air Layer is a mass of hot, dry air laden with dust that forms over the Sahara and moves towards the Atlantic Ocean. This air mass contains soil dust particles emitted by the action of winds on the African continent. Between June and August, the large-scale patterns of wind circulation transport dust from the Sahara across the tropical North Atlantic Ocean,affecting parts of the Caribbean, Central America, Mexico, even some regions of the United States, and the Mediterranean and Southern Europe. Between December and April, wind circulation patterns facilitate dust transportation from the Sahara to the northern parts of South America and the Amazon. This dust transportation a phenomenon of interest to geosciencesand public health because of the potential health impacts of dust dispersion and circulation in the atmosphere. Thus, we assessed the relationship between exposure to Saharan dust (SahD) and its implications for human health in the Americas. We performed a nonsystematic review in the PubMed, Google Scholar, EMBASE, and Scielo databases of studies published between 2000 and 2020 in Portuguese, English, French, or Spanish using the search words “Saharan dust,” or “mineral dust,” or “desert dust,” and “human health.” The available direct air pollutants measurements indicate that the pollution level in the cities affected on a constant and prolonged basis is high versus acceptable standards. Further, this review also showed that the negative health effects of SahD are sparsely studied in the Americas.
Published: 2021
Full Text: View/download PDF

20. Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non–Critically Ill Hospitalized Patients With Diabetes

Author: Alexandra Migdal, Rodolfo J. Galindo, Georgia Davis, Kashif M. Munir, William H. Scott, Rebecca M. Doerfler, Sergio Lizama, Medha Satyarengga, Francisco J. Pasquel, Lakshmi G. Singh, Maria A. Urrutia, Priyathama Vellanki, Bonnie S. Albury, Guillermo E. Umpierrez, Saumeth Cardona, K. Walkiria Zamudio-Coronado, Elias K. Spanakis, and Limin Peng
Subjects: Research design, Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Type 2 diabetes, Hypoglycemia, Interquartile range, Diabetes management, Diabetes mellitus, Internal medicine, Emerging Technologies: Data Systems and Devices, Internal Medicine, medicine, Humans, Aged, Retrospective Studies, Advanced and Specialized Nursing, business.industry, Insulin, Blood Glucose Self-Monitoring, Reproducibility of Results, Middle Aged, medicine.disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Ambulatory, business
Abstract: OBJECTIVE Advances in continuous glucose monitoring (CGM) have transformed ambulatory diabetes management. Until recently, inpatient use of CGM has remained investigational, with limited data on its accuracy in the hospital setting. RESEARCH DESIGN AND METHODS To analyze the accuracy of Dexcom G6, we compared retrospective matched-pair CGM and capillary point-of-care (POC) glucose data from three inpatient CGM studies (two interventional and one observational) in general medicine and surgery patients with diabetes treated with insulin. Analysis of accuracy metrics included mean absolute relative difference (MARD), median absolute relative difference (ARD), and proportion of CGM values within 15, 20, and 30% or 15, 20, and 30 mg/dL of POC reference values for blood glucose >100 mg/dL or ≤100 mg/dL, respectively (% 15/15, % 20/20, % 30/30). Clinical reliability was assessed with Clarke error grid (CEG) analyses. RESULTS A total of 218 patients were included (96% with type 2 diabetes) with a mean age of 60.6 ± 12 years. The overall MARD (n = 4,067 matched glucose pairs) was 12.8%, and median ARD was 10.1% (interquartile range 4.6, 17.6]. The proportions of readings meeting % 15/15, % 20/20, and % 30/30 criteria were 68.7, 81.7, and 93.8%, respectively. CEG analysis showed 98.7% of all values in zones A and B. MARD and median ARD were higher in the case of hypoglycemia ( CONCLUSIONS Our results indicate that CGM technology is a reliable tool for hospital use and may help improve glucose monitoring in non–critically ill hospitalized patients with diabetes.
Published: 2021

21. Hospital admission for symptoms exacerbation in 2,075 infants suffering from recurrent asthma-like symptoms (EISL-3 South America)

Author: Javier Mallol, Dirceu Solé, Carolina Aranda, Eliana C. Toledo, Viviana Aguirre, Marilyn Urrutia-Pereira, Gabriela A. Szulman, Nelson Rosario, Herberto Chong, Líllian Sanchez-Lacerda, Jurg Niederbacher, Catalina Pinchak, Patricia Polles de Olivera, Erika Arruda-Chávez, Luis García-Marcos, and null EISL Phase 3 Study Group South America
Subjects: Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Pregnancy, Exacerbation, business.industry, Immunology, Breastfeeding, General Medicine, Prenatal smoking, medicine.disease, Logistic regression, South american, Hospital admission, medicine, Immunology and Allergy, business, Asthma
Abstract: Background: Contrary to what happens in children and adults, the prevalence and the factors related to hospitalisation for asthma/wheezing in infants with recurrent asthma-like symptoms are poorly known.Methods: This study is part of the International Study of Wheezing in infants Phase 3; 2,079 infants (aged 12–18 months) with recurrent asthma-like symptoms, from 11 South American centres, were studied to determine the prevalence and the associated factors for wheezing exacerbation admission. Descriptive statistics and multivariate logistic regression were employed for analysis.Results: The prevalence of admission for wheezing was 29.7% (95% CI 27.7–31.6) and was significantly associated to severe wheezing episodes (OR: 3.89; 95% CI: 2.93–5.18, p < 0.001), physician-diagnosed asthma (OR: 1.79; 95% CI: 1.33–2.41, p < 0.0001), use of inhaled corticosteroids (OR: 1.78; 95%CI: 1.38–2.29, p < 0.0001), maternal tobacco smoking during pregnancy (OR:1.69; 95% CI: 1.19–2.39, p = 0.003) and onset of wheezing in the first trimester of life (OR: 1.30; 95% CI: 1.02–1.66, p = 0.038). Breast feeding ≥4 months (OR: 0.72; 95% CI: 0.54–0.96, p = 0.004), maternal high educational level (>12 years) (OR: 0.66; 95% CI: 0.51–0.85, p = 0.001) and total monthly household income ≥US$ 3,000 (OR: 0.34; 95% CI: 0.18–0.67, p = 0.002), were protective factors.Conclusions: Infants with recurrent asthma-like symptoms have a high rate of admissions. Tobacco smoking in pregnancy, viral respiratory illness in the first trimester of life and severe progression were risks for admissions. Improving medical management to prevent severe exacerbations, prolonging the postnatal period at home longer than 3 months, favouring breastfeeding and avoiding smoking during pregnancy may have a preventive role for admissions in infants with recurrent asthma-like symptoms.
Published: 2021
Full Text: View/download PDF

22. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

Author: Javier Domínguez-Ortega, Iñigo Ojanguren, Gregorio Soto, José María Vega Chicote, Antonio Parra Arrondo, Miguel Perpiñá, Carolina Cisneros, Isabel Urrutia, Juan Luis García-Rivero, Eva Martínez-Moragón, Carlos Almonacid, Valentina Gutiérrez Vall De Cabrës, Irina Bobolea, Antolín López Viña, Marina Blanco, Dario Antolin, Astrid Crespo, Alfons Torrego, Joaquín Sastre Domínguez, Paloma Campo Mozo, Victoria García Gallardo, Vicente Plaza, Mar Mosteiro, Ismael García Moguel, Ignacio Dávila, Carlos Colás, Aythamy Henrquez Santana, Luis Pérez de Llano, Alicia Habernau Mena, Francisco Álvarez, Juan Carlos Miralles, Remedios Cardenas Contreras, Borja G. Cosío, Manuel Jorge Rial Prado, César Picado, Loreto Carmona, José María Olaguibel Rivera, Xavi Muñoz, Santiago Quirce Gancedo, Pilar Barranco Sanz, José Ramón Serrano, Ignacio Antepara Ercoreca, Julio Delgado Romero, Cristian Domingo, and María Jesús García de Yébenes
Subjects: medicine.medical_specialty, Potentially all pairwise rankings of all possible alternatives, business.industry, Maintenance dose, medicine.drug_class, Intraclass correlation, Minimal clinically important difference, Context (language use), medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Internal medicine, medicine, Immunology and Allergy, Corticosteroid, 030212 general & internal medicine, business, Face validity, Asthma
Abstract: Background There is a lack of tools to quantify the response to monoclonal antibodies (mAbs) holistically in severe uncontrolled asthma patients. Objective To develop a valid score to assist specialists in this clinical context. Methods The score was developed in four subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis using the Potentially All Pairwise RanKings of All Possible Alternatives methodology using the 1000minds software; and (4) face validity assessment of the obtained score. Results Four core items, with different levels of response for each, were selected: severe exacerbations, oral corticosteroid use, symptoms (evaluated by Asthma Control Test), and bronchial obstruction (assessed by FEV1 percent predicted). Severe exacerbations and oral corticosteroid maintenance dose were weighted most heavily (38% each), followed by symptoms (13%) and FEV1 (11%). Higher scores in the weighted system indicate a better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient of 0.86). Conclusions The FEV1, exacerbations, oral corticosteroids, symptoms score allows clinicians to quantify response in severe uncontrolled asthma patients who are being treated with mAbs.
Published: 2021
Full Text: View/download PDF

23. An independent inter- and intraobserver agreement assessment of the AOSpine sacral fracture classification system

Author: Manuel Valencia, Ratko Yurac, Julio Urrutia, Marcelo Valacco, Gaston Camino-Willhuber, Arturo Meissner-Haecker, and Nelson Astur
Subjects: Sacrum, Context (language use), Classification scheme, 03 medical and health sciences, 0302 clinical medicine, Cohen's kappa, Humans, Medicine, Orthopedics and Sports Medicine, In patient, Prospective Studies, Observer Variation, 030222 orthopedics, business.industry, Reproducibility of Results, Sacral fracture, Sagittal plane, medicine.anatomical_structure, Coronal plane, Spinal Fractures, Surgery, Neurology (clinical), business, Nuclear medicine, 030217 neurology & neurosurgery
Abstract: BACKGROUND CONTEXT The AOSpine sacral classification scheme was recently described. It demonstrated substantial interobserver and excellent intraobserver agreement in the study describing it; however, an independent assessment has not been performed. PURPOSE To perform an independent inter- and intraobserver agreement evaluation of the AOSpine sacral fracture classification system. STUDY DESIGN Agreement study. METHODS Complete computerized tomography (CT) scans, including axial images, with coronal and sagittal reconstructions of 80 patients with sacral fractures were selected and classified using the morphologic grading of the AOSpine sacral classification system by six evaluators (from three different countries). Neurological modifiers and case-specific modifiers were not assessed. After a four-week interval, the 80 cases were presented to the same raters in a random sequence for repeat assessment. We used the Kappa coefficient (κ) to establish the inter- and intraobserver agreement. RESULTS The interobserver agreement was substantial when considering the fracture severity types (A, B, or C), with κ=0.68 (0.63–0.72), but moderate when considering the subtypes: κ=0.52 (0.49–0.54). The intraobserver agreement was substantial considering the fracture types, with κ=0.69 (0.63–0.75), and considering subtypes, κ=0.61 (0.56–0.67). CONCLUSION The sacral classification system allows adequate interobserver agreement at the type level, but only moderate at the subtypes level. Future prospective studies should evaluate whether this classification system allows surgeons to decide the best treatment and to establish prognosis in patients with sacral fractures.
Published: 2021
Full Text: View/download PDF

24. Conocimiento de las iniciativas de adecuación de la práctica clínica en profesionales de hospital

Author: P. Tudela, G. Ezcurra, A. Urrutia, and C. Gaona
Subjects: business.industry, Medicine, General Medicine, business, Humanities
Published: 2022
Full Text: View/download PDF

25. Hospital health personnel’s knowledge of initiatives on the appropriateness of clinical practice

Author: A. Urrutia, G. Ezcurra, C. Gaona, and P. Tudela
Subjects: Clinical Practice, Health Knowledge, Attitudes, Practice, Health personnel, Nursing, business.industry, Health Personnel, Humans, Medicine, General Medicine, business, Hospitals
Published: 2022
Full Text: View/download PDF

26. BJS commission on surgery and perioperative care post-COVID-19

Author: E. Abahuje, A. Abbas, M. Abd El Aziz Abd El Maksoud, A. Abdelhady, S. Abdelhamid, H. Abdelkarem Ahmed Faraj, B. Abdelqader, T. Abdelrahman, H. Abdou, A. Abdullah, M. Abedua Harrison, E. Abem Owusu, A. Aboalazayem, R. Aboulhosn, S. Abu Oda, A. Abubakar, A. Abutaka, D. Acevedo Fontalvo, S. Acuna, A. Adefemi, S. Adegbola, T. Adenuga, A. Adeyeye, A. Adil Hilmi, A. Adisa, K. Aditya, T. Adjeso, R. Aftab, A. Afzal, V. Aggarwal, A. Aggarwal, R. Aguilera, M. -L. Aguilera-Are´valo, E. J. Aguirre Salamanca, I. Aguirre-Allende, D. Ahari, H. Ahmad, F. Ahmad Rauf, A. Ahmad Zartasht Khan, S. Ahmed, N. Ahmed Fieturi, S. Ahmed Mohamed, Z. Ahmed-Bakhsh, M. Ahsan Javed, L. Akano, A. Akbar, M. Akhbari, P. Akhmedov, G. Aksit, Y. Akula, A. S. Alagaratnam, S. Al Majid, O. Al Mukhtar, H. Al Omran, N. AlAsali, M. Al-Azzawi, R. Al-Habsi, H. Al-Iraqi, H. Al-Naggar, E. Alameer, H. Albirnawi, D. Alderson, F. Aldulaijan, R. Alejandro Miranda Ojeda, A. AlHasan, S. Ali, A. Ali, M. Ali Khan, Y. Alimova, F. Aljanadi, R. Aljubure, N. Allopi, H. Almedbal, M. Almubarak, Z. Alqaidoom, N. Alselaim, M. Alshaar, R. Alshammari, K. Altaf, S. Altıner, B. Altunpak, L. A. Alvarez Lozada, E. Amal Nahal, A. Amer, K. Amin, U. Aminu, N. Amisi Numbi, T. Amjad, R. Amoah, Y. An, N. -A. Anastasopoulos, J. Andre´s Urrutia, F. Angarita, K. -L. Angarita, M. A´ ngel FreirI´a Eiras, A. Antypas, M. A. Anwar, H. Anwar, T. O. Apampa, K. Apostolou, C. Aquina, R. Arachchige Adithi Himika Randeni, M. I. Archila Godı´nez, O. Arez, A. A. Arezzo, P. Armonis, S. Arshad, M. Arshad Salman, A. Arshid, P. C. Arteaga Asensio, T. Arthur, A. Arumuga Jothi, F. Aryo Damara, L. Asensio Gomez, J. Ashcroft, S. Ashraf, A. Asif, M. Atif, M. Attaullah Khan, N. Avellaneda, S. Awad, M. Awadh, A. Axiaq, A. Ayad Mohammed Shuwayyah, D. Ayalew, E. Aytac, F. Azam, J. Azevedo, B. Azhar, J. Aziz, A. Aziz, A. Azzam, A. Baba Ndajiwo, M. Baig, D. Baker, F. Bakko, R. Balachandran, G. Balachandran, J. Balagizi Mudekereza, E. Balai, B. Balci, A. Balduzzi, A. Balhareth, S. Bandyopadhyay, D. Banerjee, D. Bangalore Mahalinga, B. Bankhead-Kendall, N. D. A. Bankole, V. Banwell, F. Baris Bengur, B. Baris Ozmen, M. Barnard, R. Barnett, J. A. Barreras Espinoza, A. Barrios, G. Bass, M. Bass, A. Bausys, A. Bavikatte, J. Bayram, M. Belousov, A. G. Berardi, A. Beamish, C. Beattie, F. Belia, V. Bellato, S. Bellikatti, S. Benjamens, C. Benlice, S. Bennedsgaard, S. Bennett, Z. Bentounsi, H. Bergenfeldt, A. Bergenfelz, M. Besselink, G. Bhandoria, E. Bhangu, M. Bhatia, M. T. Bhatti, Z. Bilgili, G. Bislenghi, C. Bisset, S. Biswas, J. Blake, R. Blanco, L. Boccalatte, R. Boden, C. Bojanic, M. Boland, P. Boland, E. Bollen, E. -A. Bonci, L. Boni, A. Booth, R. Booth, A. Borakati, G. E. Borunda Escudero, S. J. Bosco, P. Bostro¨ m, P. Botelho de Alencar Ferreira Cruz, K. Bouchagier, A. Bouhuwaish, M. Boutros, K. Boyce, C. Boyle, L. Bradshaw, A. Brandl, A. Brar, G. Brat, H. Brenkman, C. Brennan, C. Brines, A. Brookmyre, C. Brosnan, L. Brouwers, A. Brown, L. Brown, C. Brown, J. Brown, V. BS, M. Buksh, M. Bunani Emmanuel, D. Burbano, A. Burelli, A. Burke, J. Burke, N. Burlov, A. Burns, O. Burton, A. Butt, B. Buzra Ozkan, L. Cabrera Silva, E. Y. Caicedo, T. Calderbank, W. Cambridge, G. Campelo, O. Can Tatar, F. Carbone, F. Carrano, D. Casallas, D. Casanova Portoles, F. Casciani, I. Cassimjee, O. A. Castaneda Ramı´rez, V. Catala´ n, J. Caviedes, L. Cayetano, M. ~ Ceresoli, M. Chan, V. Chan, P. Chandrasinghe, S. Chapman, A. Chaturvedi, D. Chaudhry, H. Chaudry, H. W. Chen, A. Cheng, M. Chernykh, A. M. Cherrie, I. Cheruiyot, J. Cheung, C. Chia, J. Chica, N. Chinai, A. Chirwa, J. Chiwaligo, A. Choi, J. Choi, M. R. Chowdhury, E. Christopher, N. Christou, T. Chu, D. Chua, H. W. Chua, C. Chung, A. Cihat Yildirim, M. Cillo, S. Cioffi, H. Claireaux, S. Clermonts, R. Clifford, M. Climent, A. Clynch, R. -J. Coelen, E. Cola´ s-Ruiz, A. Collar, M. Collard, K. C. Conlon, T. Connelly, K. Connor, J. A. Cook, T. Correia de Sa´, N. Cos¸gun Acar, T. Costa, D. Couch, S. Cowper, B. Creavin, B. Crook, A. Curell, R. D’alessio, J. Dale, J. Damgaard Eriksen, I. Dario Martin Gonzalez, A. Darwish, M. Das, R. Das, K. Das, R. Dave, S. O. David, T. Davies, C. Davis, S. Davison, V. Davletshina, A. Dawidziuk, A. Dawson, M. de Andres Crespo, H. de Berker, P. de Dieu Ngo, E. Dekker, R. de la Caridad Espinosa Luis, B. de Lacy, N. Demartines, A. de Montserrat Medina Sifuentes, S. De Silva, C. del Rio, V. Delaune, A. Dell, I. Demirbas¸, S. Demirli Atici, M. Deniz Tepe, M. Derebey, G. Desai, M. Desai, S. Devarakonda, N. Deveras, G. Di Franco, M. Di Martino, F. Di Marzo, A´ . Dı´az, G. Diaz del Gobbo, C. DiazCastrillon, L. Dick, K. Dickinson, E. Diego, I. Dimasi, A. Ding, S. Dingemans, L. Dixon, B. Dixon, W. Doherty, D. Dooreemeah, C. Donohue, M. Dornseifer, F. Dossa, W. Dossou, T. Drake, I. Drami, G. Drevin, M. C. du Plessis, N. Dudi-Venkata, R. Dudley, S. Duffy, D. Duklas, B. -D. Dumbrava, F. Duygu Avlar, A. Dworzynska, W. Ebrahim, A. Ebrahim, E. Efre´n Lozada Herna´ ndez, N. Ehigie, M. El Boghdady, C. El Hasnaoui, M. El Sheikh, A. El-Hussuna, O. Eldurssi, H. Elfeki, M. Elhadi, M. Elhassan, A. Elhissi, B. Elliot, C. Elsenbroek, B. Elsolh, N. Elson, H. Eltyeb, H. Emerson, S. H. Emile, G. Endalle, W. English, C. Ercisli, G. Espinosa, M. Essam Abdelraheem, H. Essangri, P. Etienne, M. D. Evans, T. Evans, C. Ezeme, F. Ezzahraa, T. Fadalla, J. Fagan, M. Fahmy, C. Fairfield, O. Falade, S. Famularo, F. Faqar-Uz-Zaman, Y. Farid, A. Farooq, H. Farooq, F. Farooqui, B. Farquharson, A. Faruqi, R. Faulder, M. Faut, K. Fechner, T. Feenstra, M. Fehervari, L. Fernandez, J. Ferna´ ndez Alberti, L. Ferrario, D. Field, L. Fiore, S. Fingerhut, S. Finlayson, N. Fleming, C. Fleming, E. Florial, M. Fok, D. Fokin, M. Foley, M. P. Forero, T. Forgan, M. Fornasiero, H. Fowler, G. Fowler, E. Franchi, L. Franklin, A˚ . Fredriksson, P. Fruhling, G. Fuentes Navarrette, A. Fu¨ lo¨ p, M. Furtado, T. Gaarder, N. Galbraith, I. T. K. Gallagher, G. Gallo, T. Gana, E. Gaskin, M. Gasparini, R. G. Gatan, E. Geary, K. Gelaye Wudineh, G. Gemenetzis, M. Georgi, H. Ghalige, W. Ghareeb, T. Ghatwary Tantawy, C. Ghomsi, A. Ghuman, P. Giannakis, F. Giron, K. Gjengedal, E. Gkotsis, J. Glasbey, S. Godahewa, D. Godula, P. Goffredo, S. Goh, M. Golriz, L. Gomez, D. Gomez Gomez, R. Gonzalez, D. Gonzalez, E. Gonzalez Gutierrez, D. Gopar, L. Gordini, A. Gori, S. Gorta´ zar, N. Gousy, R. Gowda, M. Gowda, J. Gqada, M. Grechenig, J. Greer, L. Grego´ rio, A. Grigorova, H. Grimes, V. Groot, R. C. Grossman, R. Gruber, A. Gru¨ ter, R. Guest, R. Gujjuri, E. Gu¨ lc¸ek, B. Gulcu, K. Gull, M. Gulmez, V. Gupta, A. Gutlic, T. Guven, T. Gwatirisa, G. Gwini, P. Gwodog, S. Gysling, M. Habib, A. B. Hafeez Bhatti, J. Hallesmith, S. Halloran, M. Hamza Sadiq, C. Haney, N. Hanna, L. Hanna, M. Hannington, J. Harbjerg, D. Haribaskaran, N. Harran, B. Harrington, E. Harrison, R. Hasan, S. Hashmi, M. Hassan, A. Hassan, L. Haverkamp, S. Hazen, B. Heer, J. Heil, J. Helliwell, N. Henriksen, D. Henshall, M. Hermanson, S. Hermena, D. Hettiarachchi, C. Hextall, M. Hidalgo, H. Hidayat, A. Hider, P. Higgins, R. Hinchliffe, D. Hirani, D. Hirpara, I. Hisham, M. Hite, S. M. Hoh, C. Holmberg, E. Ho¨ lmich, F. Holst, A. Hossam, A. Hossam Elfallal, P. Howard, E. Huaman, Y. Huang, L. Huang, D. Huang, T. Huber, J. Hugh, J. Hughes, F. Hu¨ ttner, R. Huynh, A. Hylands, J. Iannuzzi, B. Ielpo, A. Iftikhar Talib, J. Ignacio, P. Ignatavicius, S. Ike, C. Ikwu, M. Inama, A. Ing, A. Ingels, A. Isik, N. Islam, I. J. Ives, A. J. M. S. AlHasan, C. J. Perez Rivera, F. Ja´ come, T. Jaffer, O. Jagiella-Lodise, M. Jain, K. Jain, M. Jakubauskas, M. Jalal, H. James, Y. Jang, B. Janssen, H. Jansson, U´ . Jariod-Ferrer, H. Javanmard, S. Javed, U. Jayarajah, I. Jayasuriya, J. Je, Z. Jessop, E. Jia Lin Tang, H. Jiang, Y. Jiayan, T. Jih Huei, R. Jimenez-Rodriguez, D. Joh, A. Johnson, N. Jones, C. Jones, C. Jordan, J. Jose´ Nu´ nez Ju, ~ M. Jose´ Pizarro, C. Jose Salazar J. Joseph, C. Justiniano, T. Kabir, M. Kadhum, C. Kalfountzos, E. Kalogiannaki, K. Kalyanasundaram, S. Kamarajah, M. Kamil Quraishi, Y. Kanemitsu, A. Kapila, V. Kapila, G. Karagiannidis, M. Kashif, S. Kathiravelupillai, A. Kathiravelupillai, E. Katsogridakis, K. Kaur, H. Kaur Sekhon Inderjit Singh, N. Kausur, M. Kawka, G. Keehan, S. Kehlet Watt, M. Kelly, M. E. Kelly, I. Kelvin Egbuchulem, G. Kembuan, E. Khajeh, A. Khaled Elfaitur, M. F. Khan, S. Khan, M. Khan, D. Khan, H. Khan, H. Khatkar, E. Khatkov, R. Khaw, B. Kim, K. Kishore Siddiraju, D. Kitua, B. Kırımtay, S. Kmezic, S. Knight, T. Koe¨ter, A. Koh, F. Koh Hong Xiang, T. Kojo Anyomih, A. I. N. Kok, R. Kokelaar, I. Koliarakis, S. Kolli, J. Kong, D. Ko¨ nig, M. otze, A. Kourdouli, M. Kowal, A. Kraima, F. Kramer, M. Kryzauskas, I. Kuchynskyi, C. Kuemmerli, S. Kuiper, S. Kumar, A. Kumar, L. Kumar, H. Kumar, N. Kumar, S. Kumar Bandyopadhyay, P. Kumar Garg, S. Kumar Venkatappa, J. Kung, S. Kural, A. Kushairi, E. Kuuzie, M. Kvietkauskas, I. Kwek, J. La, L. Lai, S. Lakpriya, K. Lam, M. Lami, I. Lansdorp-Vogelaar, P. Lapolla, H. Larsen, J. Latif, U. Laudari, A. Laurnezi, A. Lawal, S. Lawday, H. Lederhuber, A. Lednev, R. Lee, M. E. van Leerdam, G. Lefevbre, M. Lesmus, F. A. Leyva Moraga, E. Leyva Moraga, F. Leyva Moraga, H. L. Li, A. Li, Z. Li, E. Licardie, A. Light, A. L. Lightner, A. Lin, E. Lincango, F. Litta, H. Liu, B. Lofthouse, M. A. Londono, R. Lopes, R. Lopes de Freitas, L. Lopez, A. I. Lo´ pez, J. ~ Lopez-Gomez, G. Lopez-Pena, R. Lowe, D. Lowe, M. Lowey, G. Loy, V. Lozanovski, J. Luzon, P. Lynn, T. Maccabe, A. Machielsen, C. A. Mafla Herrerı´a, L. Maggino, K. Mahawar, D. Mahmood, M. Mahmoud, K. Mahtani, I. Maitra, S. Maji, I. Majiet, L. Mal, J. Malherbe, K. Malhotra, P. Malkomes, E. Man, A. Manan Sheikh, S. Manjunath, R. Manzano Nunez, S. Manzoor, R. Maqsood, G. ~ Marchegiani, F. Marchegiani, D. Marı´n, A. Marin, I. Marks, E. Marson, A. Martensen, D. Martin, G. Martı´n Martı´n, B. Martin-Perez, P. Martinez, P. Marwaha, C. Mashauri, H. Mashbari, Ł. Masior, R. Masri, L. Masud, S. Masudi, G. Mateu Calabuig, S. Math, A. Matrachisia, J. Mayol, D. Mazingi, A. Mazzotta, J. McAlinden, G. McCabe, L. McColm, H. McElvaney, K. McGivern, J. McGovern, E. McGuinness, N. McInerney, S. Mckay, C. McKee, M. McKenna, N. McKenna, K. McLean, S. Mediratta, Y. Medkova, O. Medzhidov, A. Mehraj, M. Mekhael, O. Mekinde, C. Mellenthin, A. Melucci, K. Mentor, J. Merchant, H. Messias, M. Messeha, C. Meza, P. Mhango, M. Miladinov, M. Milagros Niquen Jimenez, P. Miller, E. Mills, A. Milton, O. A. Minayeva, Z. MinHua Zheng, H. Mischlinger, B. Mo¨ ckli, R. Modi, H. M. Mohamed, M. Mohamed, T. Mohamed Abulghasm, S. A. Mohammad, T. O. Mohammed, A. Mohammed, H. Mohan, M. Mohan, I. Moin, V. Mok, G. Molina, J. Moloney, J. Moneim, M. Monfort Mira, B. Montcusı´ Ventura, M. Montouri, M. Moossdorff, I. Mora-Guzma´ n, B. Moran, R. A. R. Mora´ n, S. Moreno-Ordaz, A´ . Morera, R. Morgan, R. Morley, D. Moro-Valdezate, S. Moros, J. -L. Moss, A. Morven, D. Morton, A. Moynihan, M. Moyo´ n, N. Muduli, N. Mugla, W. Mugla, P. Mu¨ ller, G. Mun, R. Mundhada, I. Munir, F. Munoz, E. Mu ~ noz, A. Mu ~ noz, D. ~ C. Munoz Balderas, E. Murgitroyd, V. Murray, S. Murthy, W. ~ Mushiwokufa, H. Mustafa, B. Mustakimov, P. Mutambanengwe, P. Myint, S. Nadkarni, P. A. Naess, S. Nahar, P. Naidoo, R. Nam, S. Nandhra, N. Nanjappa, V. Narasimhan, W. Nardi, M. Nasir, A. Naughton, D. Naumann, S. Navarro, M. Nawaaz Karimbocus, A. Nazir, S. Ndereya, A. Ndong, I. Negoi, D. Nel, D. Nelson, S. Nepal, T. Nugent, D. Nepogodiev, J. Neufeld, J. Ng, D. Ng, C. E. Ng, S. Ngaserin, L. Ngu, E. Ngwenya, R. N. Fhearaigh, T. -K. Nikolousakis, M. Ninkovic, G. Nita, C. Nitschke, E. Noren, T. Noton, A. Novikova, Z. Nowinka, T. Nyakunengwa, A. Nyalundja, I. Nzenwa, H. Ø Kristensen, C. O’Brien, L. O’Brien, S. O’Brien, J. O’Reilly, S. O’Rourke, M. O’Sullivan, M. O’Dwyer, L. Ochieng, E. Oderoha, K. E. Oh, L. O¨ hlberger, M. O¨ lc¸u¨ m, A. Olkina, M. Omkumar, B. Omnitel, D. Oncel Yakar, K. Ong, L. Ong Wei Lin, R. Ooi, S. Ooi, A. Oomman, D. Oon Tyjet, S. Opiyo, J. J. Oscullo Yepez, N. Osei-kuffour, T. Osunronbi, A. Ottlaka´ n, S. Oussama Kacimi, S. Ovaere, A. Ozair, F. Pachler, S. Pai Oo, S. Paiella, L. Panaiotti, N. Panda, S. Pandarinath, D. Pandey, S. Pandrowala, F. Papa Mamadou, M. Paranathala, J. Park, C. Parmar, A. Parvez, L. Pasovic, A. Pasquer, N. Pasumarthy, F. Pata, T. Patel, P. Patel, N. Patel, M. Patel, N. Patron Uriburu, R. Patrone, A. Paul, O. M. Pavan Kumar, A. Pavithran, M. Pedraza Ciro, G. Pellino, A. Peloso, M. T. Pena~ Gallardo, A. Pena Velazquez, J. Perea, L. E. Pe´rez-Sa´ nchez, T. ~ Perra, G. Perrotta, P. Petersson, G. Petra, N. Petrucciani, C. Pickin, V. Pino, E. Pinotti, F. Pinto, P. Plum, F. Podesta, T. Pollini, M. Pompeu Sa´, F. Ponce Leon, H. S. Ponniah, X. Ponte de Sousa, J. Ponton, A. Pontula, M. Popa, A. L. Portilla, F. Posner, S. Post, A. Potolicchio, S. Pouwels, A. Povo, P. Prasad, S. Preciado, R. Preece, D. Proud, J. A. Pulido Segura, N. Puliyath, M. Qui, A. S. Quimbaya Rodrı´guez, W. Raby-Smith, A. Racovit¸a, A. Rad, R. Radwan, M. Rafaih Iqbal, A. Rafik, B. Raguan, M. Rahi, J. -L. Rahiri, J. Rahme, L. Rai, A. Raj, A. Raj Saksena, M. Raja, J. Ramirez, J. Ramzi, J. Ranstam, C. Rao, A. Rashid, B. Ratnayake, K. Rattanasirivilai, K. Raubenheimer, N. Ravikumar, S. Ravn, N. Razoz, W. Rea, A. Regan, M. Rela, A. Remme, C. E. Rey Chaves, A. Reyes, A. Riad, D. Rice, K. Rios Quintana, A. Ritter, M. Roalsø, D. Robinson, J. Rodriguez, F. Rodrı´guez, M. C. Rodriguez, A. Rogers, J. Rohila, D. Romanyuc, I. Romic, M. Rommaneh, G. Rompianesi, F. Rosa, F. Roscio, A. Rose, T. Rotimi, H. Ruiz, J. Ruiz Yucuma, E. Ruiz-U´ car, M. Ruslan, M. Rutega˚ rd, E. Ryan Harper, A. Ryckx, D. Rydbeck, E. Fonseca, A. Sanchez Teran, S. Sanchez Ussa, O. Sandli, H. Sanfey, J. Sanghera, I. Sani, M. Santafe Guerrero, M. Sante Fornasiero, O. Santes Jasso, I. Santos Pereira, H. Santos Sousa, A. Saratzis, A. Sarmiento Alarcon, T. Saumtally, R. Sayyed, M. Schettino, L. Schleimer, T. Schmidt, K. Schondffelt, M. Schwab, A. Scott, H. Searle, L. Sebopelo, B. Seeglier, R. Seishima, D. Semenvov, A. Senent-Boza, J. Sepulveda, M. Serenari, M. Serrano Navidad, I. Sert, E. Sewart, A. Sgro`, V. Shadrina, K. Shah, F. Shahid, M. Shalaby, B. Shankar, J. Shapiro, L. Sharma, A. Sheel, A. Shenfine, S. Shenoy, A. Sherif, N. Shetty, R. Shetty, T. C. Sia, D. Sichimba, H. Siddique, I. Siddiqui, G. Simkens, J. Simoe, H. Simon, L. Sinan, T. Singh, K. Singh, Y. Singh, L. Sinha, L. Siragusa, T. Sluckin, Y. W. Smart, H. Smith, K. Smith, L. Smits, C. Sneep-van Kessel, C. Sohrabi, O. Solo´ rzano Pineda, A. Soma, L. Sooriyapiragasam, K. Søreide, M. Sparavigna, R. Spence, N. Spencer, H. Spiers, A. Spinelli, J. Sprakel, S. Sravanam, M. Srinivasan, R. Srinivasan, A. Staniszewska, S. J. Stanworth, K. Stasinos, R. J. C. Steele, I. Steinholt, M. Steinruecke, B. -J. Stephen, J. Stijns, M. Still, W. Stupalkowska, S. Subba, V. V. Subbotin, P. Sucharitkul, A. Sudarsanam, D. Sudhamsh Reddy, T. Suhardja, M. Suliman, M. Sund, A. Sunilkumar, N. Suresh, S. Sussmes, P. Sutton, J. Syltern, A. Taha, Y. Takamizawa, A. B. Takoutsing Dongmo, T. Tama´ s, L. Tan, J. L. Tan, K. Tan, E. Tan, A. Tan Yong Hui, A. Tanase, A. Tariverdiev, A. Tasnem, C. Tatar, E. Tay, P. Tejedor, G. Tesfaye, F. Tetinou, C. Thorpe, A. Thyø, D. Tlelo Amastal, M. Tolani, K. Tolga Saracoglu, T. To¨ lgyes, J. Tong, L. Torrent Jansa`, S. Toscano Igartua, M. R. Tovani Palone, H. Traff, J. Trevis, W. Tummers, A. Tur, I. Turchenko, V. Uche, A. Uddin, N. Udonsak, M. Ullah, T. Urbonas, C. Uwins, E. Uy Magadia, A. Uzair Qureshi, K. Uzun, P. Vadim, G. Valarche, R. A. Valdez Gonzalez, M. Vallee, D. -J. van Beek, A. S. van Dalen, D. van den Hondel, E. van der stok, M. van Dorp, S. van Oostendorp, E. van Praag, J. van Rees, L. van Silfhout, Z. Varga, S. Varghese, C. Varghese, J. Varghese, A. -M. Vasilica, X. Va´ squez Ojeda, E. Vega, S. Vehler, R. Venchiarutti, S. Vengatesan, M. Venn, D. Verma, G. Vianey Partida Nava, D. Victoria, P. Vieira, M. E. Vilar Alvarez, D. Vinci, G. Viscasillas Palla` s, M. Viswanath, J. Vivanco, V. Vizcaya Rodrı´guez, J. Vo, D. Volchanski, T. Voron, Y. Voronovskyi, J. Vu, M. Wadhwa, S. Wadhwa, G. Wagner, M. Wallace, Y. Y. Wang, J. Wang, A. Wani, K. Wanigasooriya, S. Wanjara, N. Wanjiku, C. Warner, T. Wei Leow, T. Weiser, M. Weisters, M. J. Wellington, C. Wells, C. Wenzelberg, D. Wettstein, A. Wezel, L. Wheldon, L. Widmer, M. Wilson, S. Wigmore, T. Wijayaratne, M. Wijeyaratne, B. P. L. 1176 | BJS, 2021, Vol. 108, No. 10 Sá-Marta, I. Sadien, D. SafariNteranya, K. Sagoo, S. Sakata, E. Saladino, A. Saleem, S. Saleem, M. Salehi, S. Salih, V. Sallinen, S. Salvans, Z. H. Sam, E. Samadov, M. Sampaio Alves, A. Sanad, S. Sánchez Wijnhoven, R. Wilkin, E. Williams, F. Willis, D. Winter, M. M. Wirsik, B. Wishah, G. Wong, W. J. Wong, K. Wong, K. -Y. Wong, D. Worku, E. Wright, J. Wright, O. Wroe Wright, S. Xenacki, W. Xia, W. Xu, Z. Xu, A. Yalcinkaya, W. Yang, P. -C. Yang, A. Yanishev, A. Yanzon de la Torre, H. Yao, E. Yaqoob, S. Yen Ling Quake, D. Yeo, B. Yeom, D. Yershov, M. Yiasemidou, A. Yildiz, A. Yiu, M. Yoav, E. Yong, R. Yoshimura, M. U. Younis, Z. Younis Ringshawl, M. Youssef, Y. Yue, S. Yuen, R. Yuldashev, C. Yurttas, B. Yves, A. Zaborowski, R. Zackeri, A. Zafar, W. Zahra, A. Zaidi, S. Zainudin, R. Zakeri, I. Zamora, A. T. Zamora, M. Zawistowski, G. Zbikowska, W. Zegers, S. Zehra, A. Zeyra, Z. Zhagniyev, L. G. Zhukova, M. Zivanovic, J. Zmuc, M. Zope, A. Zubayraeva, B. Zucker., Abahuje, E., Abbas, A., Abd El Aziz Abd El Maksoud, M., Abdelhady, A., Abdelhamid, S., Abdelkarem Ahmed Faraj, H., Abdelqader, B., Abdelrahman, T., Abdou, H., Abdullah, A., Abedua Harrison, M., Abem Owusu, E., Aboalazayem, A., Aboulhosn, R., Abu Oda, S., Abubakar, A., Abutaka, A., Acevedo Fontalvo, D., Acuna, S., Adefemi, A., Adegbola, S., Adenuga, T., Adeyeye, A., Adil Hilmi, A., K. Aditya, A. Adisa, Adjeso, T., Aftab, R., Afzal, A., Aggarwal, V., Aggarwal, A., Aguilera, R., Aguilera-Are´valo, M. -L., Aguirre Salamanca, E. J., Aguirre-Allende, I., Ahari, D., Ahmad, H., Ahmad Rauf, F., Ahmad Zartasht Khan, A., Ahmed, S., Ahmed Fieturi, N., Ahmed Mohamed, S., Ahmed-Bakhsh, Z., Ahsan Javed, M., Akano, L., Akbar, A., Akhbari, M., Akhmedov, P., Aksit, G., Akula, Y., Alagaratnam, A. S., Al Majid, S., Al Mukhtar, O., Al Omran, H., Alasali, N., Al-Azzawi, M., Al-Habsi, R., Al-Iraqi, H., Al-Naggar, H., Alameer, E., Albirnawi, H., Alderson, D., Aldulaijan, F., Alejandro Miranda Ojeda, R., Alhasan, A., Ali, S., Ali, A., Ali Khan, M., Alimova, Y., Aljanadi, F., Aljubure, R., Allopi, N., Almedbal, H., Almubarak, M., Alqaidoom, Z., Alselaim, N., Alshaar, M., Alshammari, R., Altaf, K., Altıner, S., Altunpak, B., Alvarez Lozada, L. A., Amal Nahal, E., Amer, A., Amin, K., Aminu, U., Amisi Numbi, N., Amjad, T., Amoah, R., An, Y., Anastasopoulos, N. -A., Andre´s Urrutia, J., Angarita, F., Angarita, K. -L., A´ ngel FreirI´a Eiras, M., Antypas, A., Anwar, M. A., Anwar, H., Apampa, T. O., Apostolou, K., Aquina, C., Arachchige Adithi Himika Randeni, R., Archila Godı´nez, M. I., Arez, O., Arezzo, A. A., Armonis, P., Arshad, S., Arshad Salman, M., Arshid, A., Arteaga Asensio, P. C., Arthur, T., Arumuga Jothi, A., Aryo Damara, F., Asensio Gomez, L., Ashcroft, J., Ashraf, S., Asif, A., Atif, M., Attaullah Khan, M., Avellaneda, N., Awad, S., Awadh, M., Axiaq, A., Ayad Mohammed Shuwayyah, A., Ayalew, D., Aytac, E., Azam, F., Azevedo, J., Azhar, B., Aziz, J., Aziz, A., Azzam, A., Baba Ndajiwo, A., Baig, M., Baker, D., Bakko, F., Balachandran, R., Balachandran, G., Balagizi Mudekereza, J., Balai, E., Balci, B., Balduzzi, A., Balhareth, A., Bandyopadhyay, S., Banerjee, D., Bangalore Mahalinga, D., Bankhead-Kendall, B., Bankole, N. D. A., Banwell, V., Baris Bengur, F., Baris Ozmen, B., Barnard, M., Barnett, R., Barreras Espinoza, J. A., Barrios, A., Bass, G., Bass, M., Bausys, A., Bavikatte, A., Bayram, J., Belousov, M., Berardi, A. G., Beamish, A., Beattie, C., Belia, F., Bellato, V., Bellikatti, S., Benjamens, S., Benlice, C., Bennedsgaard, S., Bennett, S., Bentounsi, Z., Bergenfeldt, H., Bergenfelz, A., Besselink, M., Bhandoria, G., Bhangu, E., Bhatia, M., Bhatti, M. T., Bilgili, Z., Bislenghi, G., Bisset, C., Biswas, S., Blake, J., Blanco, R., Boccalatte, L., Boden, R., Bojanic, C., Boland, M., Boland, P., Bollen, E., Bonci, E. -A., Boni, L., Booth, A., Booth, R., Borakati, A., Borunda Escudero, G. E., Bosco, S. J., Bostro¨ m, P., Botelho de Alencar Ferreira Cruz, P., Bouchagier, K., Bouhuwaish, A., Boutros, M., Boyce, K., Boyle, C., Bradshaw, L., Brandl, A., Brar, A., Brat, G., Brenkman, H., Brennan, C., Brines, C., Brookmyre, A., Brosnan, C., Brouwers, L., Brown, A., Brown, L., Brown, C., Brown, J., Bs, V., Buksh, M., Bunani Emmanuel, M., Burbano, D., Burelli, A., Burke, A., Burke, J., Burlov, N., Burns, A., Burton, O., Butt, A., Buzra Ozkan, B., Cabrera Silva, L., Caicedo, E. Y., Calderbank, T., Cambridge, W., Campelo, G., Can Tatar, O., Carbone, F., Carrano, F., Casallas, D., Casanova Portoles, D., Casciani, F., Cassimjee, I., Castaneda Ramı´rez, O. A., Catala´ n, V., Caviedes, J., Cayetano, L., ~ Ceresoli, M., Chan, M., Chan, V., Chandrasinghe, P., Chapman, S., Chaturvedi, A., Chaudhry, D., Chaudry, H., Chen, H. W., Cheng, A., Chernykh, M., Cherrie, A. M., Cheruiyot, I., Cheung, J., Chia, C., Chica, J., Chinai, N., Chirwa, A., Chiwaligo, J., Choi, A., Choi, J., Chowdhury, M. R., Christopher, E., Christou, N., Chu, T., Chua, D., Chua, H. W., Chung, C., Cihat Yildirim, A., Cillo, M., Cioffi, S., Claireaux, H., Clermonts, S., Clifford, R., Climent, M., Clynch, A., Coelen, R. -J., Cola´ s-Ruiz, E., Collar, A., Collard, M., Conlon, K. C., Connelly, T., Connor, K., Cook, J. A., Correia de Sa´, T., Cos¸gun Acar, N., Costa, T., Couch, D., Cowper, S., Creavin, B., Crook, B., Curell, A., D’Alessio, R., Dale, J., Damgaard Eriksen, J., Dario Martin Gonzalez, I., Darwish, A., Das, M., Das, R., Das, K., Dave, R., David, S. O., Davies, T., Davis, C., Davison, S., Davletshina, V., Dawidziuk, A., Dawson, A., de Andres Crespo, M., de Berker, H., de Dieu Ngo, P., Dekker, E., de la Caridad Espinosa Luis, R., de Lacy, B., Demartines, N., de Montserrat Medina Sifuentes, A., De Silva, S., del Rio, C., Delaune, V., Dell, A., Demirbas¸, I., Demirli Atici, S., Deniz Tepe, M., Derebey, M., Desai, G., Desai, M., Devarakonda, S., Deveras, N., Di Franco, G., Di Martino, M., Di Marzo, F., Dı´az, A´., Diaz del Gobbo, G., Diazcastrillon, C., Dick, L., Dickinson, K., Diego, E., Dimasi, I., Ding, A., Dingemans, S., Dixon, L., Dixon, B., Doherty, W., Dooreemeah, D., Donohue, C., Dornseifer, M., Dossa, F., Dossou, W., Drake, T., Drami, I., Drevin, G., du Plessis, M. C., Dudi-Venkata, N., Dudley, R., Duffy, S., Duklas, D., Dumbrava, B. -D., Duygu Avlar, F., Dworzynska, A., Ebrahim, W., Ebrahim, A., Efre´n Lozada Herna´ ndez, E., Ehigie, N., El Boghdady, M., El Hasnaoui, C., El Sheikh, M., El-Hussuna, A., Eldurssi, O., Elfeki, H., Elhadi, M., Elhassan, M., Elhissi, A., Elliot, B., Elsenbroek, C., Elsolh, B., Elson, N., Eltyeb, H., Emerson, H., Emile, S. H., Endalle, G., English, W., Ercisli, C., Espinosa, G., Essam Abdelraheem, M., Essangri, H., Etienne, P., Evans, M. D., Evans, T., Ezeme, C., Ezzahraa, F., Fadalla, T., Fagan, J., Fahmy, M., Fairfield, C., Falade, O., Famularo, S., Faqar-Uz-Zaman, F., Farid, Y., Farooq, A., Farooq, H., Farooqui, F., Farquharson, B., Faruqi, A., Faulder, R., Faut, M., Fechner, K., Feenstra, T., Fehervari, M., Fernandez, L., Ferna´ ndez Alberti, J., Ferrario, L., Field, D., Fiore, L., Fingerhut, S., Finlayson, S., Fleming, N., Fleming, C., Florial, E., Fok, M., Fokin, D., Foley, M., Forero, M. P., Forgan, T., Fornasiero, M., Fowler, H., Fowler, G., Franchi, E., Franklin, L., Fredriksson, A˚., Fruhling, P., Fuentes Navarrette, G., Fu¨ lo¨ p, A., Furtado, M., Gaarder, T., Galbraith, N., Gallagher, I. T. K., Gallo, G., Gana, T., Gaskin, E., Gasparini, M., Gatan, R. G., Geary, E., Gelaye Wudineh, K., Gemenetzis, G., Georgi, M., Ghalige, H., Ghareeb, W., Ghatwary Tantawy, T., Ghomsi, C., Ghuman, A., Giannakis, P., Giron, F., Gjengedal, K., Gkotsis, E., Glasbey, J., Godahewa, S., Godula, D., Goffredo, P., Goh, S., Golriz, M., Gomez, L., Gomez Gomez, D., Gonzalez, R., Gonzalez, D., Gonzalez Gutierrez, E., Gopar, D., Gordini, L., Gori, A., Gorta´ zar, S., Gousy, N., Gowda, R., Gowda, M., Gqada, J., Grechenig, M., Greer, J., Grego´ rio, L., Grigorova, A., Grimes, H., Groot, V., Grossman, R. C., Gruber, R., Gru¨ ter, A., Guest, R., Gujjuri, R., Gu¨ lc¸ek, E., Gulcu, B., Gull, K., Gulmez, M., Gupta, V., Gutlic, A., Guven, T., Gwatirisa, T., Gwini, G., Gwodog, P., Gysling, S., Habib, M., Hafeez Bhatti, A. B., Hallesmith, J., Halloran, S., Hamza Sadiq, M., Haney, C., Hanna, N., Hanna, L., Hannington, M., Harbjerg, J., Haribaskaran, D., Harran, N., Harrington, B., Harrison, E., Hasan, R., Hashmi, S., Hassan, M., Hassan, A., Haverkamp, L., Hazen, S., Heer, B., Heil, J., Helliwell, J., Henriksen, N., Henshall, D., Hermanson, M., Hermena, S., Hettiarachchi, D., Hextall, C., Hidalgo, M., Hidayat, H., Hider, A., Higgins, P., Hinchliffe, R., Hirani, D., Hirpara, D., Hisham, I., Hite, M., Hoh, S. M., Holmberg, C., Ho¨ lmich, E., Holst, F., Hossam, A., Hossam Elfallal, A., Howard, P., Huaman, E., Huang, Y., Huang, L., Huang, D., Huber, T., Hugh, J., Hughes, J., Hu¨ ttner, F., Huynh, R., Hylands, A., Iannuzzi, J., Ielpo, B., Iftikhar Talib, A., Ignacio, J., Ignatavicius, P., Ike, S., Ikwu, C., Inama, M., Ing, A., Ingels, A., Isik, A., Islam, N., Ives, I. J., Alhasan, A. J. M. S., Perez Rivera, C. J., Ja´ come, F., Jaffer, T., Jagiella-Lodise, O., Jain, M., Jain, K., Jakubauskas, M., Jalal, M., James, H., Jang, Y., Janssen, B., Jansson, H., Jariod-Ferrer, U´., Javanmard, H., Javed, S., Jayarajah, U., Jayasuriya, I., Je, J., Jessop, Z., Jia Lin Tang, E., Jiang, H., Jiayan, Y., Jih Huei, T., Jimenez-Rodriguez, R., Joh, D., Johnson, A., Jones, N., Jones, C., Jordan, C., Jose´ Nu´ nez Ju, J., Jose´ Pizarro, ~ M., Joseph, C. Jose Salazar J., Justiniano, C., Kabir, T., Kadhum, M., Kalfountzos, C., Kalogiannaki, E., Kalyanasundaram, K., Kamarajah, S., Kamil Quraishi, M., Kanemitsu, Y., Kapila, A., Kapila, V., Karagiannidis, G., Kashif, M., Kathiravelupillai, S., Kathiravelupillai, A., Katsogridakis, E., Kaur, K., Kaur Sekhon Inderjit Singh, H., Kausur, N., Kawka, M., Keehan, G., Kehlet Watt, S., Kelly, M., Kelly, M. E., Kelvin Egbuchulem, I., Kembuan, G., Khajeh, E., Khaled Elfaitur, A., Khan, M. F., Khan, S., Khan, M., Khan, D., Khan, H., Khatkar, H., Khatkov, E., Khaw, R., Kim, B., Kishore Siddiraju, K., Kitua, D., Kırımtay, B., Kmezic, S., Knight, S., Koe¨ter, T., Koh, A., Koh Hong Xiang, F., Kojo Anyomih, T., Kok, A. I. N., Kokelaar, R., Koliarakis, I., Kolli, S., Kong, J., Ko¨ nig, D., Otze, M., Kourdouli, A., Kowal, M., Kraima, A., Kramer, F., Kryzauskas, M., Kuchynskyi, I., Kuemmerli, C., Kuiper, S., Kumar, S., Kumar, A., Kumar, L., Kumar, H., Kumar, N., Kumar Bandyopadhyay, S., Kumar Garg, P., Kumar Venkatappa, S., Kung, J., Kural, S., Kushairi, A., Kuuzie, E., Kvietkauskas, M., Kwek, I., La, J., Lai, L., Lakpriya, S., Lam, K., Lami, M., Lansdorp-Vogelaar, I., Lapolla, P., Larsen, H., Latif, J., Laudari, U., Laurnezi, A., Lawal, A., Lawday, S., Lederhuber, H., Lednev, A., Lee, R., van Leerdam, M. E., Lefevbre, G., Lesmus, M., Leyva Moraga, F. A., Leyva Moraga, E., Leyva Moraga, F., Li, H. L., Li, A., Li, Z., Licardie, E., Light, A., Lightner, A. L., Lin, A., Lincango, E., Litta, F., Liu, H., Lofthouse, B., Londono, M. A., Lopes, R., Lopes de Freitas, R., Lopez, L., Lo´ pez, A. I., ~ Lopez-Gomez, J., Lopez-Pena, G., Lowe, R., Lowe, D., Lowey, M., Loy, G., Lozanovski, V., Luzon, J., Lynn, P., Maccabe, T., Machielsen, A., Mafla Herrerı´a, C. A., Maggino, L., Mahawar, K., Mahmood, D., Mahmoud, M., Mahtani, K., Maitra, I., Maji, S., Majiet, I., Mal, L., Malherbe, J., Malhotra, K., Malkomes, P., Man, E., Manan Sheikh, A., Manjunath, S., Manzano Nunez, R., Manzoor, S., Maqsood, R., ~ Marchegiani, G., Marchegiani, F., Marı´n, D., Marin, A., Marks, I., Marson, E., Martensen, A., Martin, D., Martı´n Martı´n, G., Martin-Perez, B., Martinez, P., Marwaha, P., Mashauri, C., Mashbari, H., Masior, Ł., Masri, R., Masud, L., Masudi, S., Mateu Calabuig, G., Math, S., Matrachisia, A., Mayol, J., Mazingi, D., Mazzotta, A., Mcalinden, J., Mccabe, G., Mccolm, L., Mcelvaney, H., Mcgivern, K., Mcgovern, J., Mcguinness, E., Mcinerney, N., Mckay, S., Mckee, C., Mckenna, M., Mckenna, N., Mclean, K., Mediratta, S., Medkova, Y., Medzhidov, O., Mehraj, A., Mekhael, M., Mekinde, O., Mellenthin, C., Melucci, A., Mentor, K., Merchant, J., Messias, H., Messeha, M., Meza, C., Mhango, P., Miladinov, M., Milagros Niquen Jimenez, M., Miller, P., Mills, E., Milton, A., Minayeva, O. A., MinHua Zheng, Z., Mischlinger, H., Mo¨ ckli, B., Modi, R., Mohamed, H. M., Mohamed, M., Mohamed Abulghasm, T., Mohammad, S. A., Mohammed, T. O., Mohammed, A., Mohan, H., Mohan, M., Moin, I., Mok, V., Molina, G., Moloney, J., Moneim, J., Monfort Mira, M., Montcusı´ Ventura, B., Montouri, M., Moossdorff, M., Mora-Guzma´ n, I., Moran, B., Mora´ n, R. A. R., Moreno-Ordaz, S., Morera, A´., Morgan, R., Morley, R., Moro-Valdezate, D., Moros, S., Moss, J. -L., Morven, A., Morton, D., Moynihan, A., Moyo´ n, M., Muduli, N., Mugla, N., Mugla, W., Mu¨ ller, P., Mun, G., Mundhada, R., Munir, I., Munoz, F., Mu ~ noz, E., Mu ~ noz, A., Munoz Balderas, D. ~ C., Murgitroyd, E., Murray, V., Murthy, S., ~ Mushiwokufa, W., Mustafa, H., Mustakimov, B., Mutambanengwe, P., Myint, P., Nadkarni, S., Naess, P. A., Nahar, S., Naidoo, P., Nam, R., Nandhra, S., Nanjappa, N., Narasimhan, V., Nardi, W., Nasir, M., Naughton, A., Naumann, D., Navarro, S., Nawaaz Karimbocus, M., Nazir, A., Ndereya, S., Ndong, A., Negoi, I., Nel, D., Nelson, D., Nepal, S., Nugent, T., Nepogodiev, D., Neufeld, J., Ng, J., Ng, D., Ng, C. E., Ngaserin, S., Ngu, L., Ngwenya, E., Fhearaigh, R. N., Nikolousakis, T. -K., Ninkovic, M., Nita, G., Nitschke, C., Noren, E., Noton, T., Novikova, A., Nowinka, Z., Nyakunengwa, T., Nyalundja, A., Nzenwa, I., Ø Kristensen, H., O’Brien, C., O’Brien, L., O’Brien, S., O’Reilly, J., O’Rourke, S., O’Sullivan, M., O’Dwyer, M., Ochieng, L., Oderoha, E., Oh, K. E., O¨ hlberger, L., O¨ lc¸u¨ m, M., Olkina, A., Omkumar, M., Omnitel, B., Oncel Yakar, D., Ong, K., Ong Wei Lin, L., Ooi, R., Ooi, S., Oomman, A., Oon Tyjet, D., Opiyo, S., Oscullo Yepez, J. J., Osei-kuffour, N., Osunronbi, T., Ottlaka´ n, A., Oussama Kacimi, S., Ovaere, S., Ozair, A., Pachler, F., Pai Oo, S., Paiella, S., Panaiotti, L., Panda, N., Pandarinath, S., Pandey, D., Pandrowala, S., Papa Mamadou, F., Paranathala, M., Park, J., Parmar, C., Parvez, A., Pasovic, L., Pasquer, A., Pasumarthy, N., Pata, F., Patel, T., Patel, P., Patel, N., Patel, M., Patron Uriburu, N., Patrone, R., Paul, A., Pavan Kumar, O. M., Pavithran, A., Pedraza Ciro, M., Pellino, G., Peloso, A., Pena~ Gallardo, M. T., Pena Velazquez, A., Perea, J., Pe´rez-Sa´ nchez, L. E., ~ Perra, T., Perrotta, G., Petersson, P., Petra, G., Petrucciani, N., Pickin, C., Pino, V., Pinotti, E., Pinto, F., Plum, P., Podesta, F., Pollini, T., Pompeu Sa´, M., Ponce Leon, F., Ponniah, H. S., Ponte de Sousa, X., Ponton, J., Pontula, A., Popa, M., Portilla, A. L., Posner, F., Post, S., Potolicchio, A., Pouwels, S., Povo, A., Prasad, P., Preciado, S., Preece, R., Proud, D., Pulido Segura, J. A., Puliyath, N., Qui, M., Quimbaya Rodrı´guez, A. S., Raby-Smith, W., Racovit¸a, A., Rad, A., Radwan, R., Rafaih Iqbal, M., Rafik, A., Raguan, B., Rahi, M., Rahiri, J. -L., Rahme, J., Rai, L., Raj, A., Raj Saksena, A., Raja, M., Ramirez, J., Ramzi, J., Ranstam, J., Rao, C., Rashid, A., Ratnayake, B., Rattanasirivilai, K., Raubenheimer, K., Ravikumar, N., Ravn, S., Razoz, N., Rea, W., Regan, A., Rela, M., Remme, A., Rey Chaves, C. E., Reyes, A., Riad, A., Rice, D., Rios Quintana, K., Ritter, A., Roalsø, M., Robinson, D., Rodriguez, J., Rodrı´guez, F., Rodriguez, M. C., Rogers, A., Rohila, J., Romanyuc, D., Romic, I., Rommaneh, M., Rompianesi, G., Rosa, F., Roscio, F., Rose, A., Rotimi, T., Ruiz, H., Ruiz Yucuma, J., Ruiz-U´ car, E., Ruslan, M., Rutega˚ rd, M., Ryan Harper, E., Ryckx, A., Rydbeck, D., Fonseca, E., Sanchez Teran, A., Sanchez Ussa, S., Sandli, O., Sanfey, H., Sanghera, J., Sani, I., Santafe Guerrero, M., Sante Fornasiero, M., Santes Jasso, O., Santos Pereira, I., Santos Sousa, H., Saratzis, A., Sarmiento Alarcon, A., Saumtally, T., Sayyed, R., Schettino, M., Schleimer, L., Schmidt, T., Schondffelt, K., Schwab, M., Scott, A., Searle, H., Sebopelo, L., Seeglier, B., Seishima, R., Semenvov, D., Senent-Boza, A., Sepulveda, J., Serenari, M., Serrano Navidad, M., Sert, I., Sewart, E., Sgro`, A., Shadrina, V., Shah, K., Shahid, F., Shalaby, M., Shankar, B., Shapiro, J., Sharma, L., Sheel, A., Shenfine, A., Shenoy, S., Sherif, A., Shetty, N., Shetty, R., Sia, T. C., Sichimba, D., Siddique, H., Siddiqui, I., Simkens, G., Simoe, J., Simon, H., Sinan, L., Singh, T., Singh, K., Singh, Y., Sinha, L., Siragusa, L., Sluckin, T., Smart, Y. W., Smith, H., Smith, K., Smits, L., Sneep-van Kessel, C., Sohrabi, C., Solo´ rzano Pineda, O., Soma, A., Sooriyapiragasam, L., Søreide, K., Sparavigna, M., Spence, R., Spencer, N., Spiers, H., Spinelli, A., Sprakel, J., Sravanam, S., Srinivasan, M., Srinivasan, R., Staniszewska, A., Stanworth, S. J., Stasinos, K., Steele, R. J. C., Steinholt, I., Steinruecke, M., Stephen, B. -J., Stijns, J., Still, M., Stupalkowska, W., Subba, S., Subbotin, V. V., Sucharitkul, P., Sudarsanam, A., Sudhamsh Reddy, D., Suhardja, T., Suliman, M., Sund, M., Sunilkumar, A., Suresh, N., Sussmes, S., Sutton, P., Syltern, J., Taha, A., Takamizawa, Y., Takoutsing Dongmo, A. B., Tama´ s, T., Tan, L., Tan, J. L., Tan, K., Tan, E., Tan Yong Hui, A., Tanase, A., Tariverdiev, A., Tasnem, A., Tatar, C., Tay, E., Tejedor, P., Tesfaye, G., Tetinou, F., Thorpe, C., Thyø, A., Tlelo Amastal, D., Tolani, M., Tolga Saracoglu, K., To¨ lgyes, T., Tong, J., Torrent Jansa`, L., Toscano Igartua, S., Tovani Palone, M. R., Traff, H., Trevis, J., Tummers, W., Tur, A., Turchenko, I., Uche, V., Uddin, A., Udonsak, N., Ullah, M., Urbonas, T., Uwins, C., Uy Magadia, E., Uzair Qureshi, A., Uzun, K., Vadim, P., Valarche, G., Valdez Gonzalez, R. A., Vallee, M., van Beek, D. -J., van Dalen, A. S., van den Hondel, D., van der stok, E., van Dorp, M., van Oostendorp, S., van Praag, E., van Rees, J., van Silfhout, L., Varga, Z., Varghese, S., Varghese, C., Varghese, J., Vasilica, A. -M., Va´ squez Ojeda, X., Vega, E., Vehler, S., Venchiarutti, R., Vengatesan, S., Venn, M., Verma, D., Vianey Partida Nava, G., Victoria, D., Vieira, P., Vilar Alvarez, M. E., Vinci, D., Viscasillas Palla` s, G., Viswanath, M., Vivanco, J., Vizcaya Rodrı´guez, V., Vo, J., Volchanski, D., Voron, T., Voronovskyi, Y., Vu, J., Wadhwa, M., Wadhwa, S., Wagner, G., Wallace, M., Wang, Y. Y., Wang, J., Wani, A., Wanigasooriya, K., Wanjara, S., Wanjiku, N., Warner, C., Wei Leow, T., Weiser, T., Weisters, M., Wellington, M. J., Wells, C., Wenzelberg, C., Wettstein, D., Wezel, A., Wheldon, L., Widmer, L., Wilson, M., Wigmore, S., Wijayaratne, T., Wijeyaratne, M., 1176 | BJS, B. P. L., 108, Vol., 10 Sá-Marta, No., Sadien, I., Safarinteranya, D., Sagoo, K., Sakata, S., Saladino, E., Saleem, A., Saleem, S., Salehi, M., Salih, S., Sallinen, V., Salvans, S., Sam, Z. H., Samadov, E., Sampaio Alves, M., Sanad, A., Sánchez Wijnhoven, S., Wilkin, R., Williams, E., Willis, F., Winter, D., Wirsik, M. M., Wishah, B., Wong, G., Wong, W. J., Wong, K., Wong, K. -Y., Worku, D., Wright, E., Wright, J., Wroe Wright, O., Xenacki, S., Xia, W., Xu, W., Xu, Z., Yalcinkaya, A., Yang, W., Yang, P. -C., Yanishev, A., Yanzon de la Torre, A., Yao, H., Yaqoob, E., Yen Ling Quake, S., Yeo, D., Yeom, B., Yershov, D., Yiasemidou, M., Yildiz, A., Yiu, A., Yoav, M., Yong, E., Yoshimura, R., Younis, M. U., Younis Ringshawl, Z., Youssef, M., Yue, Y., Yuen, S., Yuldashev, R., Yurttas, C., Yves, B., Zaborowski, A., Zackeri, R., Zafar, A., Zahra, W., Zaidi, A., Zainudin, S., Zakeri, R., Zamora, I., Zamora, A. T., Zawistowski, M., Zbikowska, G., Zegers, W., Zehra, S., Zeyra, A., Zhagniyev, Z., Zhukova, L. G., Zivanovic, M., Zmuc, J., Zope, M., Zubayraeva, A., Zucker., B., Abahuje, E, Abbas, A, Abd El Aziz Abd El Maksoud, M, Abdelhady, A, Abdelhamid, S, Abdelkarem Ahmed Faraj, H, Abdelqader, B, Abdelrahman, T, Abdou, H, Abdullah, A, Abedua Harrison, M, Abem Owusu, E, Aboalazayem, A, Aboulhosn, R, Abu Oda, S, Abubakar, A, Abutaka, A, Acevedo Fontalvo, D, Acuna, S, Adefemi, A, Adegbola, S, Adenuga, T, Adeyeye, A, Adil Hilmi, A, Adisa, A, Aditya, K, Adjeso, T, Aftab, R, Afzal, A, Aggarwal, V, Aggarwal, A, Aguilera, R, Aguilera-Arevalo, M, Aguirre Salamanca, E, Aguirre-Allende, I, Ahari, D, Ahmad, H, Ahmad Rauf, F, Ahmad Zartasht Khan, A, Ahmed, S, Ahmed Fieturi, N, Ahmed Mohamed, S, Ahmed-Bakhsh, Z, Ahsan Javed, M, Akano, L, Akbar, A, Akhbari, M, Akhmedov, P, Aksit, G, Akula, Y, Alagaratnam, A, Al Majid, S, Al Mukhtar, O, Al Omran, H, Alasali, N, Al-Azzawi, M, Al-Habsi, R, Al-Iraqi, H, Al-Naggar, H, Alameer, E, Albirnawi, H, Alderson, D, Aldulaijan, F, Alejandro Miranda Ojeda, R, Alhasan, A, Ali, S, Ali, A, Ali Khan, M, Alimova, Y, Aljanadi, F, Aljubure, R, Allopi, N, Almedbal, H, Almubarak, M, Alqaidoom, Z, Alselaim, N, Alshaar, M, Alshammari, R, Altaf, K, Altiner, S, Altunpak, B, Alvarez Lozada, L, Amal Nahal, E, Amer, A, Amin, K, Aminu, U, Amisi Numbi, N, Amjad, T, Amoah, R, An, Y, Anastasopoulos, N, Andres Urrutia, J, Angarita, F, Angarita, K, Angel Freiria Eiras, M, Antypas, A, Anwar, M, Anwar, H, Apampa, T, Apostolou, K, Aquina, C, Arachchige Adithi Himika Randeni, R, Archila Godinez, M, Arez, O, Arezzo, A, Armonis, P, Arshad, S, Arshad Salman, M, Arshid, A, Arteaga Asensio, P, Arthur, T, Arumuga Jothi, A, Aryo Damara, F, Asensio Gomez, L, Ashcroft, J, Ashraf, S, Asif, A, Atif, M, Attaullah Khan, M, Avellaneda, N, Awad, S, Awadh, M, Axiaq, A, Ayad Mohammed Shuwayyah, A, Ayalew, D, Aytac, E, Azam, F, Azevedo, J, Azhar, B, Aziz, J, Aziz, A, Azzam, A, Baba Ndajiwo, A, Baig, M, Baker, D, Bakko, F, Balachandran, R, Balachandran, G, Balagizi Mudekereza, J, Balai, E, Balci, B, Balduzzi, A, Balhareth, A, Bandyopadhyay, S, Banerjee, D, Bangalore Mahalinga, D, Bankhead-Kendall, B, Bankole, N, Banwell, V, Baris Bengur, F, Baris Ozmen, B, Barnard, M, Barnett, R, Barreras Espinoza, J, Barrios, A, Bass, G, Bass, M, Bausys, A, Bavikatte, A, Bayram, J, Belousov, M, Berardi, A, Beamish, A, Beattie, C, Belia, F, Bellato, V, Bellikatti, S, Benjamens, S, Benlice, C, Bennedsgaard, S, Bennett, S, Bentounsi, Z, Bergenfeldt, H, Bergenfelz, A, Besselink, M, Bhandoria, G, Bhangu, E, Bhatia, M, Bhatti, M, Bilgili, Z, Bislenghi, G, Bisset, C, Biswas, S, Blake, J, Blanco, R, Boccalatte, L, Boden, R, Bojanic, C, Boland, M, Boland, P, Bollen, E, Bonci, E, Boni, L, Booth, A, Booth, R, Borakati, A, Borunda Escudero, G, Bosco, S, Bostrom, P, Botelho De Alencar Ferreira Cruz, P, Bouchagier, K, Bouhuwaish, A, Boutros, M, Boyce, K, Boyle, C, Bradshaw, L, Brandl, A, Brar, A, Brat, G, Brenkman, H, Brennan, C, Brines, C, Brookmyre, A, Brosnan, C, Brouwers, L, Brown, A, Brown, L, Brown, C, Brown, J, Bs, V, Buksh, M, Bunani Emmanuel, M, Burbano, D, Burelli, A, Burke, A, Burke, J, Burlov, N, Burns, A, Burton, O, Butt, A, Buzra Ozkan, B, Cabrera Silva, L, Caicedo, E, Calderbank, T, Cambridge, W, Campelo, G, Can Tatar, O, Carbone, F, Carrano, F, Casallas, D, Casanova Portoles, D, Casciani, F, Cassimjee, I, Castaneda Ramirez, O, Catalan, V, Caviedes, J, Cayetano, L, Ceresoli, M, Chan, M, Chan, V, Chandrasinghe, P, Chapman, S, Chaturvedi, A, Chaudhry, D, Chaudry, H, Chen, H, Cheng, A, Chernykh, M, Cherrie, A, Cheruiyot, I, Cheung, J, Chia, C, Chica, J, Chinai, N, Chirwa, A, Chiwaligo, J, Choi, A, Choi, J, Chowdhury, M, Christopher, E, Christou, N, Chu, T, Chua, D, Chua, H, Chung, C, Cihat Yildirim, A, Cillo, M, Cioffi, S, Claireaux, H, Clermonts, S, Clifford, R, Climent, M, Clynch, A, Coelen, R, Colas-Ruiz, E, Collar, A, Collard, M, Conlon, K, Connelly, T, Connor, K, Cook, J, Correia De Sa, T, Cosgun Acar, N, Costa, T, Couch, D, Cowper, S, Creavin, B, Crook, B, Curell, A, D'Alessio, R, Dale, J, Damgaard Eriksen, J, Dario Martin Gonzalez, I, Darwish, A, Das, M, Das, R, Das, K, Dave, R, David, S, Davies, T, Davis, C, Davison, S, Davletshina, V, Dawidziuk, A, Dawson, A, De Andres Crespo, M, De Berker, H, De Dieu Ngo, P, Dekker, E, De La Caridad Espinosa Luis, R, De Lacy, B, Demartines, N, De Montserrat Medina Sifuentes, A, De Silva, S, Del Rio, C, Delaune, V, Dell, A, Demirbas, I, Demirli Atici, S, Deniz Tepe, M, Derebey, M, Desai, G, Desai, M, Devarakonda, S, Deveras, N, Di Franco, G, Di Martino, M, Di Marzo, F, Diaz, A, Diaz Del Gobbo, G, Diazcastrillon, C, Dick, L, Dickinson, K, Diego, E, Dimasi, I, Ding, A, Dingemans, S, Dixon, L, Dixon, B, Doherty, W, Dooreemeah, D, Donohue, C, Dornseifer, M, Dossa, F, Dossou, W, Drake, T, Drami, I, Drevin, G, Du Plessis, M, Dudi-Venkata, N, Dudley, R, Duffy, S, Duklas, D, Dumbrava, B, Duygu Avlar, F, Dworzynska, A, Ebrahim, W, Ebrahim, A, Efren Lozada Hernandez, E, Ehigie, N, El Boghdady, M, El Hasnaoui, C, El Sheikh, M, El-Hussuna, A, Eldurssi, O, Elfeki, H, Elhadi, M, Elhassan, M, Elhissi, A, Elliot, B, Elsenbroek, C, Elsolh, B, Elson, N, Eltyeb, H, Emerson, H, Emile, S, Endalle, G, English, W, Ercisli, C, Espinosa, G, Essam Abdelraheem, M, Essangri, H, Etienne, P, Evans, M, Evans, T, Ezeme, C, Ezzahraa, F, Fadalla, T, Fagan, J, Fahmy, M, Fairfield, C, Falade, O, Famularo, S, Faqar-Uz-Zaman, F, Farid, Y, Farooq, A, Farooq, H, Farooqui, F, Farquharson, B, Faruqi, A, Faulder, R, Faut, M, Fechner, K, Feenstra, T, Fehervari, M, Fernandez, L, Fernandez Alberti, J, Ferrario, L, Field, D, Fiore, L, Fingerhut, S, Finlayson, S, Fleming, N, Fleming, C, Florial, E, Fok, M, Fokin, D, Foley, M, Forero, M, Forgan, T, Fornasiero, M, Fowler, H, Fowler, G, Franchi, E, Franklin, L, Fredriksson, A, Fruhling, P, Fuentes Navarrette, G, Fulop, A, Furtado, M, Gaarder, T, Galbraith, N, Gallagher, I, Gallo, G, Gana, T, Gaskin, E, Gasparini, M, Gatan, R, Geary, E, Gelaye Wudineh, K, Gemenetzis, G, Georgi, M, Ghalige, H, Ghareeb, W, Ghatwary Tantawy, T, Ghomsi, C, Ghuman, A, Giannakis, P, Giron, F, Gjengedal, K, Gkotsis, E, Glasbey, J, Godahewa, S, Godula, D, Goffredo, P, Goh, S, Golriz, M, Gomez, L, Gomez Gomez, D, Gonzalez, R, Gonzalez, D, Gonzalez Gutierrez, E, Gopar, D, Gordini, L, Gori, A, Gortazar, S, Gousy, N, Gowda, R, Gowda, M, Gqada, J, Grechenig, M, Greer, J, Gregorio, L, Grigorova, A, Grimes, H, Groot, V, Grossman, R, Gruber, R, Gruter, A, Guest, R, Gujjuri, R, Gulcek, E, Gulcu, B, Gull, K, Gulmez, M, Gupta, V, Gutlic, A, Guven, T, Gwatirisa, T, Gwini, G, Gwodog, P, Gysling, S, Habib, M, Hafeez Bhatti, A, Hallesmith, J, Halloran, S, Hamza Sadiq, M, Haney, C, Hanna, N, Hanna, L, Hannington, M, Harbjerg, J, Haribaskaran, D, Harran, N, Harrington, B, Harrison, E, Hasan, R, Hashmi, S, Hassan, M, Hassan, A, Haverkamp, L, Hazen, S, Heer, B, Heil, J, Helliwell, J, Henriksen, N, Henshall, D, Hermanson, M, Hermena, S, Hettiarachchi, D, Hextall, C, Hidalgo, M, Hidayat, H, Hider, A, Higgins, P, Hinchliffe, R, Hirani, D, Hirpara, D, Hisham, I, Hite, M, Hoh, S, Holmberg, C, Holmich, E, Holst, F, Hossam, A, Hossam Elfallal, A, Howard, P, Huaman, E, Huang, Y, Huang, L, Huang, D, Huber, T, Hugh, J, Hughes, J, Huttner, F, Huynh, R, Hylands, A, Iannuzzi, J, Ielpo, B, Iftikhar Talib, A, Ignacio, J, Ignatavicius, P, Ike, S, Ikwu, C, Inama, M, Ing, A, Ingels, A, Isik, A, Islam, N, Ives, I, Al-Hasan, A, Perez Rivera, C, Jacome, F, Jaffer, T, Jagiella-Lodise, O, Jain, M, Jain, K, Jakubauskas, M, Jalal, M, James, H, Jang, Y, Janssen, B, Jansson, H, Jariod-Ferrer, U, Javanmard, H, Javed, S, Jayarajah, U, Jayasuriya, I, Je, J, Jessop, Z, Jia Lin Tang, E, Jiang, H, Jiayan, Y, Jih Huei, T, Jimenez-Rodriguez, R, Joh, D, Johnson, A, Jones, N, Jones, C, Jordan, C, Jose Nunez Ju, J, Jose Pizarro, M, Jose Salazar, C, Joseph, J, Justiniano, C, Kabir, T, Kadhum, M, Kalfountzos, C, Kalogiannaki, E, Kalyanasundaram, K, Kamarajah, S, Kamil Quraishi, M, Kanemitsu, Y, Kapila, A, Kapila, V, Karagiannidis, G, Kashif, M, Kathiravelupillai, S, Kathiravelupillai, A, Katsogridakis, E, Kaur, K, Kaur Sekhon Inderjit Singh, H, Kausur, N, Kawka, M, Keehan, G, Kehlet Watt, S, Kelly, M, Kelvin Egbuchulem, I, Kembuan, G, Khajeh, E, Khaled Elfaitur, A, Khan, M, Khan, S, Khan, D, Khan, H, Khatkar, H, Khatkov, E, Khaw, R, Kim, B, Kishore Siddiraju, K, Kitua, D, Kirimtay, B, Kmezic, S, Knight, S, Koeter, T, Koh, A, Koh Hong Xiang, F, Kojo Anyomih, T, Kok, A, Kokelaar, R, Koliarakis, I, Kolli, S, Kong, J, Konig, D, Koshy, M, Kotze, P, Kourdouli, A, Kowal, M, Kraima, A, Kramer, F, Kryzauskas, M, Kuchynskyi, I, Kuemmerli, C, Kuiper, S, Kumar, S, Kumar, A, Kumar, L, Kumar, H, Kumar, N, Kumar Bandyopadhyay, S, Kumar Garg, P, Kumar Venkatappa, S, Kung, J, Kural, S, Kushairi, A, Kuuzie, E, Kvietkauskas, M, Kwek, I, La, J, Lai, L, Lakpriya, S, Lam, K, Lami, M, Lansdorp-Vogelaar, I, Lapolla, P, Larsen, H, Latif, J, Laudari, U, Laurnezi, A, Lawal, A, Lawday, S, Lederhuber, H, Lednev, A, Lee, R, Van Leerdam, M, Lefevbre, G, Lesmus, M, Leyva Moraga, F, Leyva Moraga, E, Li, H, Li, A, Li, Z, Licardie, E, Light, A, Lightner, A, Lin, A, Lincango, E, Litta, F, Liu, H, Lofthouse, B, Londono, M, Lopes, R, Lopes De Freitas, R, Lopez, L, Lopez, A, Lopez-Gomez, J, Lopez-Pena, G, Lowe, R, Lowe, D, Lowey, M, Loy, G, Lozanovski, V, Luzon, J, Lynn, P, Maccabe, T, Machielsen, A, Mafla Herreria, C, Maggino, L, Mahawar, K, Mahmood, D, Mahmoud, M, Mahtani, K, Maitra, I, Maji, S, Majiet, I, Mal, L, Malherbe, J, Malhotra, K, Malkomes, P, Man, E, Manan Sheikh, A, Manjunath, S, Manzano Nunez, R, Manzoor, S, Maqsood, R, Marchegiani, G, Marchegiani, F, Marin, D, Marin, A, Marks, I, Marson, E, Martensen, A, Martin, D, Martin Martin, G, Martin-Perez, B, Martinez, P, Marwaha, P, Mashauri, C, Mashbari, H, Masior, L, Masri, R, Masud, L, Masudi, S, Mateu Calabuig, G, Math, S, Matrachisia, A, Mayol, J, Mazingi, D, Mazzotta, A, Mcalinden, J, Mccabe, G, Mccolm, L, Mcelvaney, H, Mcgivern, K, Mcgovern, J, Mcguinness, E, Mcinerney, N, Mckay, S, Mckee, C, Mckenna, M, Mckenna, N, Mclean, K, Mediratta, S, Medkova, Y, Medzhidov, O, Mehraj, A, Mekhael, M, Mekinde, O, Mellenthin, C, Melucci, A, Mentor, K, Merchant, J, Messias, H, Messeha, M, Meza, C, Mhango, P, Miladinov, M, Milagros Niquen Jimenez, M, Miller, P, Mills, E, Milton, A, Minayeva, O, MinHua Zheng, Z, Mischlinger, H, Mockli, B, Modi, R, Mohamed, H, Mohamed, M, Mohamed Abulghasm, T, Mohammad, S, Mohammed, T, Mohammed, A, Mohan, H, Mohan, M, Moin, I, Mok, V, Molina, G, Moloney, J, Moneim, J, Monfort Mira, M, Montcusi Ventura, B, Montouri, M, Moossdorff, M, Mora-Guzman, I, Moran, B, Moran, R, Moreno-Ordaz, S, Morera, A, Morgan, R, Morley, R, Moro-Valdezate, D, Moros, S, Moss, J, Morven, A, Morton, D, Moynihan, A, Moyon, M, Muduli, N, Mugla, N, Mugla, W, Muller, P, Mun, G, Mundhada, R, Munir, I, Munoz, F, Munoz, E, Munoz, A, Munoz Balderas, D, Murgitroyd, E, Murray, V, Murthy, S, Mushiwokufa, W, Mustafa, H, Mustakimov, B, Mutambanengwe, P, Myint, P, Nadkarni, S, Naess, P, Nahar, S, Naidoo, P, Nam, R, Nandhra, S, Nanjappa, N, Narasimhan, V, Nardi, W, Nasir, M, Naughton, A, Naumann, D, Navarro, S, Nawaaz Karimbocus, M, Nazir, A, Ndereya, S, Ndong, A, Negoi, I, Nel, D, Nelson, D, Nepal, S, Nugent, T, Nepogodiev, D, Neufeld, J, Ng, J, Ng, D, Ng, C, Ngaserin, S, Ngu, L, Ngwenya, E, Fhearaigh, R, Nikolousakis, T, Ninkovic, M, Nita, G, Nitschke, C, Noren, E, Noton, T, Novikova, A, Nowinka, Z, Nyakunengwa, T, Nyalundja, A, Nzenwa, I, Kristensen, H, O'Brien, C, O'Brien, L, O'Brien, S, O'Reilly, J, O'Rourke, S, O'Sullivan, M, O'Dwyer, M, Ochieng, L, Oderoha, E, Oh, K, Ohlberger, L, Olcum, M, Olkina, A, Omkumar, M, Omnitel, B, Oncel Yakar, D, Ong, K, Ong Wei Lin, L, Ooi, R, Ooi, S, Oomman, A, Oon Tyjet, D, Opiyo, S, Oscullo Yepez, J, Osei-Kuffour, N, Osunronbi, T, Ottlakan, A, Oussama Kacimi, S, Ovaere, S, Ozair, A, Pachler, F, Pai Oo, S, Paiella, S, Panaiotti, L, Panda, N, Pandarinath, S, Pandey, D, Pandrowala, S, Papa Mamadou, F, Paranathala, M, Park, J, Parmar, C, Parvez, A, Pasovic, L, Pasquer, A, Pasumarthy, N, Pata, F, Patel, T, Patel, P, Patel, N, Patel, M, Patron Uriburu, N, Patrone, R, Paul, A, Pavan Kumar, O, Pavithran, A, Pedraza Ciro, M, Pellino, G, Peloso, A, Pena Gallardo, M, Pena Velazquez, A, Perea, J, Perez-Sanchez, L, Perra, T, Perrotta, G, Petersson, P, Petra, G, Petrucciani, N, Pickin, C, Pino, V, Pinotti, E, Pinto, F, Plum, P, Podesta, F, Pollini, T, Pompeu Sa, M, Ponce Leon, F, Ponniah, H, Ponte De Sousa, X, Ponton, J, Pontula, A, Popa, M, Portilla, A, Posner, F, Post, S, Potolicchio, A, Pouwels, S, Povo, A, Prasad, P, Preciado, S, Preece, R, Proud, D, Pulido Segura, J, Puliyath, N, Qui, M, Quimbaya Rodriguez, A, Raby-Smith, W, Racovita, A, Rad, A, Radwan, R, Rafaih Iqbal, M, Rafik, A, Raguan, B, Rahi, M, Rahiri, J, Rahme, J, Rai, L, Raj, A, Raj Saksena, A, Raja, M, Ramirez, J, Ramzi, J, Ranstam, J, Rao, C, Rashid, A, Ratnayake, B, Rattanasirivilai, K, Raubenheimer, K, Ravikumar, N, Ravn, S, Razoz, N, Rea, W, Regan, A, Rela, M, Remme, A, Rey Chaves, C, Reyes, A, Riad, A, Rice, D, Rios Quintana, K, Ritter, A, Roalso, M, Robinson, D, Rodriguez, J, Rodriguez, F, Rodriguez, M, Rogers, A, Rohila, J, Romanyuc, D, Romic, I, Rommaneh, M, Rompianesi, G, Rosa, F, Roscio, F, Rose, A, Rotimi, T, Ruiz, H, Ruiz Yucuma, J, Ruiz-Ucar, E, Ruslan, M, Rutegard, M, Ryan Harper, E, Ryckx, A, Rydbeck, D, Sa-Marta, E, Sadien, I, Safari Nteranya, D, Sagoo, K, Sakata, S, Saladino, E, Saleem, A, Saleem, S, Salehi, M, Salih, S, Sallinen, V, Salvans, S, Sam, Z, Samadov, E, Sampaio Alves, M, Sanad, A, Sanchez Fonseca, S, Sanchez Teran, A, Sanchez Ussa, S, Sandli, O, Sanfey, H, Sanghera, J, Sani, I, Santafe Guerrero, M, Sante Fornasiero, M, Santes Jasso, O, Santos Pereira, I, Santos Sousa, H, Saratzis, A, Sarmiento Alarcon, A, Saumtally, T, Sayyed, R, Schettino, M, Schleimer, L, Schmidt, T, Schondffelt, K, Schwab, M, Scott, A, Searle, H, Sebopelo, L, Seeglier, B, Seishima, R, Semenvov, D, Senent-Boza, A, Sepulveda, J, Serenari, M, Serrano Navidad, M, Sert, I, Sewart, E, Sgro, A, Shadrina, V, Shah, K, Shahid, F, Shalaby, M, Shankar, B, Shapiro, J, Sharma, L, Sheel, A, Shenfine, A, Shenoy, S, Sherif, A, Shetty, N, Shetty, R, Sia, T, Sichimba, D, Siddique, H, Siddiqui, I, Simkens, G, Simoe, J, Simon, H, Sinan, L, Singh, T, Singh, K, Singh, Y, Sinha, L, Siragusa, L, Sluckin, T, Smart, Y, Smith, H, Smith, K, Smits, L, Sneep-Van Kessel, C, Sohrabi, C, Solorzano Pineda, O, Soma, A, Sooriyapiragasam, L, Soreide, K, Sparavigna, M, Spence, R, Spencer, N, Spiers, H, Spinelli, A, Sprakel, J, Sravanam, S, Srinivasan, M, Srinivasan, R, Staniszewska, A, Stanworth, S, Stasinos, K, Steele, R, Steinholt, I, Steinruecke, M, Stephen, B, Stijns, J, Still, M, Stupalkowska, W, Subba, S, Subbotin, V, Sucharitkul, P, Sudarsanam, A, Sudhamsh Reddy, D, Suhardja, T, Suliman, M, Sund, M, Sunilkumar, A, Suresh, N, Sussmes, S, Sutton, P, Syltern, J, Taha, A, Takamizawa, Y, Takoutsing Dongmo, A, Tamas, T, Tan, L, Tan, J, Tan, K, Tan, E, Tan Yong Hui, A, Tanase, A, Tariverdiev, A, Tasnem, A, Tatar, C, Tay, E, Tejedor, P, Tesfaye, G, Tetinou, F, Thorpe, C, Thyo, A, Tlelo Amastal, D, Tolani, M, Tolga Saracoglu, K, Tolgyes, T, Tong, J, Torrent Jansa, L, Toscano Igartua, S, Tovani Palone, M, Traff, H, Trevis, J, Tummers, W, Tur, A, Turchenko, I, Uche, V, Uddin, A, Udonsak, N, Ullah, M, Urbonas, T, Uwins, C, Uy Magadia, E, Uzair Qureshi, A, Uzun, K, Vadim, P, Valarche, G, Valdez Gonzalez, R, Vallee, M, Van Beek, D, Van Dalen, A, Van Den Hondel, D, Van Der Stok, E, Van Dorp, M, Van Oostendorp, S, Van Praag, E, Van Rees, J, Van Silfhout, L, Varga, Z, Varghese, S, Varghese, C, Varghese, J, Vasilica, A, Vasquez Ojeda, X, Vega, E, Vehler, S, Venchiarutti, R, Vengatesan, S, Venn, M, Verma, D, Vianey Partida Nava, G, Victoria, D, Vieira, P, Vilar Alvarez, M, Vinci, D, Viscasillas Pallas, G, Viswanath, M, Vivanco, J, Vizcaya Rodriguez, V, Vo, J, Volchanski, D, Voron, T, Voronovskyi, Y, Vu, J, Wadhwa, M, Wadhwa, S, Wagner, G, Wallace, M, Wang, Y, Wang, J, Wani, A, Wanigasooriya, K, Wanjara, S, Wanjiku, N, Warner, C, Wei Leow, T, Weiser, T, Weisters, M, Wellington, M, Wells, C, Wenzelberg, C, Wettstein, D, Wezel, A, Wheldon, L, Widmer, L, Wilson, M, Wigmore, S, Wijayaratne, T, Wijeyaratne, M, Wijnhoven, B, Wilkin, R, Williams, E, Willis, F, Winter, D, Wirsik, M, Wishah, B, Wong, G, Wong, W, Wong, K, Worku, D, Wright, E, Wright, J, Wroe Wright, O, Xenacki, S, Xia, W, Xu, W, Xu, Z, Yalcinkaya, A, Yang, W, Yang, P, Yanishev, A, Yanzon De La Torre, A, Yao, H, Yaqoob, E, Yen Ling Quake, S, Yeo, D, Yeom, B, Yershov, D, Yiasemidou, M, Yildiz, A, Yiu, A, Yoav, M, Yong, E, Yoshimura, R, Younis, M, Younis Ringshawl, Z, Youssef, M, Yue, Y, Yuen, S, Yuldashev, R, Yurttas, C, Yves, B, Zaborowski, A, Zackeri, R, Zafar, A, Zahra, W, Zaidi, A, Zainudin, S, Zakeri, R, Zamora, I, Zamora, A, Zawistowski, M, Zbikowska, G, Zegers, W, Zehra, S, Zeyra, A, Zhagniyev, Z, Zhukova, L, Zivanovic, M, Zmuc, J, Zope, M, Zubayraeva, A, Zucker, B, Aguilera-Arévalo, M -L, Aguirre Salamanca, E J, Al-Asali, N, Altıner, S, Alvarez Lozada, L A, Anastasopoulos, N -A, Andrés Urrutia, J, Angarita, K -L, Ángel FreirÍa Eiras, M, Anwar, M A, Apampa, T O, Archila Godínez, M I, Arteaga Asensio, P C, Bankole, N D A, Barreras Espinoza, J A, Bhatti, M T, Bonci, E -A, Borunda Escudero, G E, Bosco, S J, Boström, P, Botelho de Alencar Ferreira Cruz, P, Caicedo, E Y, Castañeda Ramírez, O A, Catalán, V, Chen, H W, Chowdhury, M R, Chua, H W, Coelen, R -J, Colás-Ruiz, E, Correia de Sá, T, Coşgun Acar, N, D’Alessio, R, David, S O, de Andres Crespo, M, de Berker, H, de Dieu Ngo, P, de la Caridad Espinosa Luis, R, de Lacy, B, de Montserrat Medina Sifuentes, A, del Rio, C, Demirbaş, I, Díaz, Á, Diaz del Gobbo, G, Diaz-Castrillon, C, du Plessis, M C, Dumbrava, B -D, Efrén Lozada Hernández, E, Fernández Alberti, J, Forero, M P, Fredriksson, Å, Fülöp, A, Gatan, R G, Gortázar, S, Gregório, L, Grüter, A, Gülçek, E, Hafeez Bhatti, A B, Hoh, S M, Hölmich, E, Hüttner, F, Alhasan, A J M S, Perez Rivera, C J, Jácome, F, Jariod-Ferrer, Ú, José, J, José Núñez Ju, J, José Pizarro, M, Khan, M F, Kırımtay, B, Kmezić, S, Koëter, T, König, D, Leyva Moraga, F A, Li, H L, Londoño, M A, Lopes de Freitas, R, López, A I, Mafla Herrería, C A, Manzano Nuñez, R, Marín, D, Martín Martín, G, Masior, Ł, Möckli, B, Mohamed, H M, Mohammad, S A, Mohammed, T O, Montcusí Ventura, B, Mora-Guzmán, I, Morán, R A R, Morera, Á, Moss, J -L, Moyón, M, Müller, P, Muñoz, F, Muñoz, E, Muñoz, A, Muñoz Balderas, D C, Ng, C E, Fhearaigh, R N, Nikolousakis, T -K, Kristensen, H Ø, O’Brien, L, O’Brien, S, O’Reilly, J, O’Rourke, S, O’Sullivan, M, O’Dwyer, M, Oh, K E, Öhlberger, L, Ölçüm, M, Oscullo Yepez, J J, Osei-kuffour, N, Ottlakán, A, Pavan Kumar, O M, Peña Gallardo, M T, Peña Velazquez, A, Pérez-Sánchez, L E, Pompeu Sá, M, Ponniah, H S, Ponte de Sousa, X, Portilla, A L, Pulido Segura, J A, Quimbaya Rodríguez, A S, Racoviţă, A, Rahiri, J -L, Rey Chaves, C E, Roalsø, M, Rodríguez, F, Rodriguez, M C, Ruiz-Úcar, E, Rutegård, M, Sá-Marta, E, Sam, Z H, Emile, Sameh H, Sánchez Fonseca, S, Sgrò, A, Sia, T C, Smart, Y W, Sneep-van Kessel, C, Solórzano Pineda, O, Stephen, B -J, Takoutsing Dongmo, A B, Tamás, T, Tan, J L, Thyø, A, Tölgyes, T, Torrent Jansà, L, Tovani Palone, M R, Valdez Gonzalez, R A, van Beek, D -J, van Dalen, A S, van den Hondel, D, van der stok, E, van Dorp, M, van Oostendorp, S, van Praag, E, van Rees, J, van Silfhout, L, Vasilica, A -M, Vásquez Ojeda, X, Vilar Alvarez, M E, Viscasillas Pallàs, G, Vizcaya Rodríguez, V, Wang, Y Y, Wellington, M J, Wirsik, M M, Wong, W J, Wong, K -Y, Wright, O Wroe, Yang, P -C, Yanzon de la Torre, A, Younis, M U, Zamora, A T, and Surgery
Subjects: Adult, Male, medicine.medical_specialty, Biomedical Research, Coronavirus disease 2019 (COVID-19), International Cooperation, Practice Patterns, Commission, Global Health, Health Services Accessibility, Perioperative Care, Education, Surgeon, COVID-19, surgery, perioperative care, Medical, Pandemic, Humans, Medicine, Practice Patterns, Physicians', Graduate, Pandemics, Surgeons, Health Resource, Infection Control, Physicians', Surgical Procedures, business.industry, General surgery, Middle Aged, Operative, Education, Medical, Graduate, Surgical Procedures, Operative, Perioperative care, Health Resources, Surgery, Female, business, Human
Abstract: Background Coronavirus disease 2019 (COVID-19) was declared a pandemic by the WHO on 11 March 2020 and global surgical practice was compromised. This Commission aimed to document and reflect on the changes seen in the surgical environment during the pandemic, by reviewing colleagues’ experiences and published evidence. Methods In late 2020, BJS contacted colleagues across the global surgical community and asked them to describe how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had affected their practice. In addition to this, the Commission undertook a literature review on the impact of COVID-19 on surgery and perioperative care. A thematic analysis was performed to identify the issues most frequently encountered by the correspondents, as well as the solutions and ideas suggested to address them. Results BJS received communications for this Commission from leading clinicians and academics across a variety of surgical specialties in every inhabited continent. The responses from all over the world provided insights into multiple facets of surgical practice from a governmental level to individual clinical practice and training. Conclusion The COVID-19 pandemic has uncovered a variety of problems in healthcare systems, including negative impacts on surgical practice. Global surgical multidisciplinary teams are working collaboratively to address research questions about the future of surgery in the post-COVID-19 era. The COVID-19 pandemic is severely damaging surgical training. The establishment of a multidisciplinary ethics committee should be encouraged at all surgical oncology centres. Innovative leadership and collaboration is vital in the post-COVID-19 era.
Published: 2021
Full Text: View/download PDF

27. Two Case Reports of Fibroid Treatment with Ulipristal Acetate Before In Vitro Fertilization

Author: Teresa Gastañaga-Holguera, Isabel Campo Gesto, Ignacio Cristóbal García, Marta Calvo Urrutia, Virginia González González, and Marta Vidaurreta Lázaro
Subjects: medicine.medical_specialty, Pregnancy, In vitro fertilisation, Obstetrics, business.industry, Uterine fibroids, Sterility, medicine.medical_treatment, Gold standard, Myoma, medicine.disease, female genital diseases and pregnancy complications, chemistry.chemical_compound, chemistry, Ulipristal acetate, medicine, business, Benign Uterine Neoplasm
Abstract: Uterine fibroids are common benign uterine neoplasms in women of reproductive age and pregnancy desire. Several surgical approaches for symptomatic fibroids are available, such as surgical or pharmacologic treatments. We report two cases of fibroids treatment with ulipristal acetate (UPA) in women with primary sterility. The first case reports a successful in vitro fertilization (IVF) after UPA as an alternative treatment to reduce the size of fibroids in a patient with two previous abdominal myomectomies, resulting in an evolutive pregnancy. The second patient is a clinical case of a successful IVF after UPA treatment in a patient with a submucous fibroid which induced myoma migration leading to its prolapse. Even though myomectomy appears to be the gold standard treatment for fibroids in women with reproductive desires, UPA treatment could be considered in those patients at high surgical risk, although more clinical series are needed to establish the safety of UPA as treatment in those women.
Published: 2021
Full Text: View/download PDF

28. Prevalence and Determinants of Tobacco Smoking Among Low-Income Urban Adolescents

Author: Augusto Matamala-Bezmalinovic, Javier Mallol, Marilyn Urrutia-Pereira, Manuel J Mallol-Simmonds, Lucas Calderón-Rodríguez, and Francisco Osses-Vergara
Subjects: Male, Pulmonary and Respiratory Medicine, Low income, medicine.medical_specialty, Passive smoking, Adolescent, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Environmental health, Prevalence, Tobacco Smoking, Humans, Immunology and Allergy, Medicine, Child, Original Research, business.industry, Public health, Smoking, Cross-Sectional Studies, 030228 respiratory system, Pediatrics, Perinatology and Child Health, Female, Tobacco Smoke Pollution, business
Abstract: Background: Tobacco-smoking in children is one of the most crucial public health concerns, which could be highly prevalent in underprivileged populations. Methods: A cross sectional, random sampling survey was conducted to determine the prevalence of current tobacco-smoking and related risk factors among adolescents living in a low-income area of Santiago de Chile. Results: Of the 2,747 adolescents participating in the study, 24.0% [95% confidence interval (CI) 22.3–25.5] were current smokers, with no significant difference between girls and boys. Factors associated with current smoking were as follows: positive attitude to smoking cigarettes offered by peers [odds ratio (OR) 8.0; 95% CI 5.7–11.3, P
Published: 2021
Full Text: View/download PDF

29. Exploring the Collateral Damage of the COVID-19 Pandemic on Stroke Care

Author: Roland Faigle, Eric Aldrich, Erin Lawrence, Clotilde Balucani, Karen Yarbrough, Victor C. Urrutia, J. Ricardo Carhuapoma, Adrian Goldszmidt, Elizabeth Marsh, Brenda Johnson, Anna Aycock, Susan Groman, Chad Schrier, Joseph K. Canner, Linda Toral, and Michael S. Phipps
Subjects: medicine.medical_specialty, Subarachnoid hemorrhage, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, 030204 cardiovascular system & hematology, Stroke care, 03 medical and health sciences, Patient Admission, 0302 clinical medicine, Acute care, Pandemic, medicine, Humans, Thrombolytic Therapy, Stroke, Cerebral Hemorrhage, Ischemic Stroke, Retrospective Studies, Thrombectomy, Advanced and Specialized Nursing, Maryland, business.industry, COVID-19, Retrospective cohort study, Thrombolysis, Subarachnoid Hemorrhage, medicine.disease, Quality Improvement, Acute Disease, Emergency medicine, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery
Abstract: Background and Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, the various emergency measures implemented to contain the spread of the virus and to overcome the volume of affected patients presenting to hospitals may have had unintended consequences. Several studies reported a decrease in the number of stroke admissions. There are no data on the impact of the COVID-19 pandemic on stroke admissions and stroke care in Maryland. Methods: A retrospective analysis of quality improvement data reported by stroke centers in the State of Maryland. The number of admissions for stroke, overall and by stroke subtype, between March 1 and September 30, 2020 (pandemic) were compared with the same time period in 2019 (prepandemic). Median last known well to hospital arrival time, the number of intravenous thrombolysis and thrombectomy were also compared. Results: During the initial 7 months of the pandemic, there were 6529 total admissions for stroke and transient ischemic attack, monthly mean 938 (95% CI, 837.1–1038.9) versus prepandemic 8003, monthly mean 1156.3 (CI, 1121.3–1191.2), P P P =0.507. Conclusions: Our findings suggest that the COVID-19 pandemic adversely affected the acute care of unrelated cerebrovascular emergencies.
Published: 2021
Full Text: View/download PDF

30. Assessment of geriatrics outcomes in the cardiac intensive care unit

Author: Usman I. Choudhry, Matthew C. Langston, Carly Fabrizio, Neil J. Wimmer, Luis Urrutia, and Keshab Subedi
Subjects: Geriatrics, education.field_of_study, medicine.medical_specialty, business.industry, Mortality rate, Population, Retrospective cohort study, Intensive care unit, law.invention, law, Intensive care, Emergency medicine, medicine, Coronary care unit, education, business, Coronary intensive care
Abstract: Objective: Critically ill older adults greater than or equal to 80 years old are routinely admitted to contemporary cardiac intensive care units (CICU). Little has been reported about their outcomes when compared to the general CICU population. The primary aim of this study was to compare the mortality, length-of-stay, and disposition outcomes of elderly patients (greater or equal to 80 years old) admitted to the CICU with a younger cohort (less than 80 years old). Methods and Results: A single-center, retrospective cohort study was conducted including 6,194 adult patients admitted to a cardiovascular intensive care unit in Newark, Delaware, from July 1, 2012, to June 30, 2019. Coronary intensive care unit (CICU) mortality, CICU length-of-stay and discharge disposition were compared between elderly patients (greater than or equal to 80 years old) and younger patients (less than 80 years old), adjusted for comorbidities. We observed increased mortality for elderly patients (OR 1.686, CI 1.361-2.090, p
Published: 2021
Full Text: View/download PDF

31. Poor re-epithelialization following corneal collagen crosslinking with riboflavin-uva for advanced bullous keratopathy: Case series

Author: B. Benito-Pascual, Pedro Arriola-Villalobos, M. Ariño-Gutiérrez, and M.T. Iradier-Urrutia
Subjects: medicine.medical_specialty, genetic structures, Riboflavin, Visual Acuity, Visual scale, 03 medical and health sciences, 0302 clinical medicine, Re-Epithelialization, Re-epithelialization, Ophthalmology, Humans, Medicine, Severe pain, Surgical treatment, Aged, High rate, Photosensitizing Agents, business.industry, Middle Aged, Corneal tomography, eye diseases, Cross-Linking Reagents, 030221 ophthalmology & optometry, Bullous keratopathy, Female, Collagen, sense organs, business
Abstract: Summary Objective To assess safety and efficacy of corneal collagen crosslinking (CXL) for advanced bullous keratopathy (BK). Material and methods Eight eyes of eight patients subjected to Dresden CXL protocol. Inclusion criteria: BK history of at least one year, severe pain and no indication for keratoplasty due to poor visual prognosis. Variables: best corrected visual acuity (BCVA), pain (decimal visual scale), central corneal thickness (CCT) by tomography (Pentacam®, Oculus Inc, Germany), corneal bullae and complications. Results Seven women and one man of median age 77.00 (range 58–79) years. The median follow-up was 7 (range 5–7) months. BCVA remained unchanged through follow-up. A significant decrease in pain was observed at the end of the follow-up period (median 6, range 5–6 vs. median 0, range 0–4, P = 0.05). Corneal tomography could only be performed in three cases, due to poor vision or image quality. A reduction in mean CCT was observed in the first post procedural month (from 708.33 ± 140.48 to 627 ± 136.89 μm). In all eight cases, the absence of corneal bullae only persisted for two months after CXL. In six patients, corneal re-epithelialization after CXL was poor; in four of these eyes, the problem was resolved with topical treatment, but in the remaining two eyes, amniotic membrane transplant and mechanical debridement were required. Conclusions In this uncontrolled small case series, CXL treatment improved pain in patients with advanced BK. However, the high rate of poor re-epithelialization requiring surgical treatment observed in one third of cases makes this treatment controversial.
Published: 2021
Full Text: View/download PDF

32. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

Author: Juan M. Fernández-Ávila, Jorge L. Azor-Hernández, Cristina O. Chávez-Chong, Klaudia Urrutia-Pérez, Lianne del Toro-Lahera, Joel Quintana-Guerra, Verena Muzio-Gonzalez, Enrique Noa-Romero, Yenima Martín-Bauta, Sergio del Valle-Piñera, Elisangela Tablada-Ferreiro, Rossana Remedios-Reyes, Gilda Lemos-Pérez, Zadis Navarro-Rodríguez, Marjoris Piñera-Martínez, Jacqueline Bizet-Almeida, Nabil A. Ali-Mros, Francisco Hernández-Bernal, Leonardo Lobaina-Lambert, Mayara Ramírez-Domínguez, José L. Rodríguez-Reinoso, Karen Urrutia-Pérez, Miladys Limonta-Fernández, Maria C. Ricardo-Cobas, Marel Alonso-Valdes, Ariel Palenzuela-Díaz, Marta Ayala-Ávila, Jeniffer Rodríguez-Nuviola, and Elizabeth Colina-Ávila
Subjects: Clinical trial, Vaccination, medicine.medical_specialty, Titer, business.industry, Vaccination schedule, Internal medicine, Immunogenicity, medicine, Seroconversion, Adverse effect, Placebo, business
Abstract: AimTo evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine (Abdala), administered intramuscularly in different strengths and vaccination schedules.MethodA phase 1-2, randomized, double-blind, placebo-controlled trial was done. Subjects were randomly distributed in 3 groups: placebo, 25 and 50µg RBD. The product was applied intramuscularly, 0.5 mL in the deltoid region. During the first phase, two immunization schedules were studied: short (0-14-28 days) and long (0-28-56 days). In phase 2, only the short scheme was evaluated. The main endpoints were: safety and proportion of subjects with seroconversion of anti-RBD IgG antibodies to SARS-CoV-2. Blood samples were collected in several points according to the corresponding vaccination schedule to determine the level of RBD-specific IgG antibodies (seroconversion rates and geometric mean of the titers), the percentage of inhibition of RBD-ACE-2 binding and levels of neutralizing antibodies.ResultsThe product was well tolerated. Severe adverse events were not reported. Adverse reactions were minimal, mostly mild and local (from the injection site), resolved in the first 24-48 hours without medication. In phase 1, at day 56 (28 days after the third dose of the short vaccination schedule, 0-14-28 days) seroconversion of anti-RBD IgG was seen in 95.2 % of the participants (20/21) for the 50μg group and 81 % of the participants (17/21) for the 25μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 80 % of the participants (8/10) for the 50μg group and 94.7% of the participants (18/19) for the 25μg group. For the long schedule, at day 70 (14 days after the third dose) seroconversion of anti-RBD IgG was seen in 100% of the participants (21/21) for the 50μg group and 94.7% of the participants (18/19) for the 25μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 95 % of the participants (19/20) for the 50μg group and 93.8% of the participants (15/16) for the 25μg group In phase 2, at day 56 seroconversion of anti-RBD IgG was seen in 89.2% of the participants (214/240) for the 50μg group, 77.7% of the participants (185/238) for the 25μg group, and 4.6% in the placebo group (11/239); whereas neutralizing antibodies to SARS-CoV-2 were seen in 97.3% of the participants (146/150) for the 50μg group and 95.1% of the participants (58/61) for the 25μg group.ConclusionAbdala vaccine against SARS-CoV-2 was safe, well tolerated and induced humoral immune responses against SARS-CoV-2 among adults from 19 to 80 years of age.Trial registration / Review protocolRPCEC00000346. Cuban Public Clinical Trial Registry (WHO accepted Primary Registry).Available from: https://rpcec.sld.cu/en/trials/RPCEC00000346-EnInformation about the ethical aspects and IRB approvalThe protocol was approved by the Ethic Committee of the participating hospital and by the Cuban Regulatory Authority (Center for State Control of Drugs, Medical Devices and Equipment).Summary boxCOVID-19 is a serious global health problem. Vaccines are urgently needed to protect humanity. Multiple vaccine candidates are currently being evaluated. The article shows promising safety and immunogenicity results for a vaccine candidate, based on the recombinant RBD subunit of the spike protein.
Published: 2021
Full Text: View/download PDF

33. Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge

Author: Gianluca Iacobellis, Maria A. Urrutia, Patricia C. Gomez, Juan D. Palacios, Priyathama Vellanki, Karla W. Z. Coronado, Georgia Davis, Francisco J. Pasquel, Rodolfo J. Galindo, Limin Peng, Bonnie S. Albury, Isabel Anzola, Javier M. Farias, Guillermo E. Umpierrez, Ajay Chaudhuri, Mireya C. Perez-Guzman, Maya Fayfman, Saumeth Cardona, and Alexandra Migdal
Subjects: Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Insulin Glargine, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, Article, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Weight loss, Internal medicine, Internal Medicine, medicine, Clinical endpoint, Humans, Hypoglycemic Agents, Adverse effect, Glycated Hemoglobin, Liraglutide, Insulin glargine, business.industry, medicine.disease, Hospitals, Patient Discharge, Treatment Outcome, Diabetes Mellitus, Type 2, Drug Therapy, Combination, medicine.symptom, business, Weight gain, medicine.drug
Abstract: AIM: To compare a glucagon-like peptide-1 receptor agonist with basal insulin at hospital discharge in patients with uncontrolled type 2 diabetes in a randomized clinical trial. METHODS: A total of 273 patients with glycated haemoglobin (HbA1c) 7%–10% (53–86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge. The primary endpoint was difference in HbA1c at 12 and 26 weeks. Secondary endpoints included hypoglycaemia, changes in body weight, and achievement of HbA1c
Published: 2021
Full Text: View/download PDF

34. Neurological manifestations temporally associated with SARS-CoV-2 infection in pediatric patients in Mexico

Author: Alejandra González-Duarte, Matilde Ruiz-García, Marta Urrutia-Osorio, Esteban Camacho-Mendoza, Gustavo Rosales-Pedraza, Patricia Herrera-Mora, Luis Dávila-Maldonado, and Areli Estela Sánchez-Morales
Subjects: Male, Pediatrics, medicine.medical_specialty, Ataxia, Adolescent, Encephalopathy, Acute ischemic stroke, Optic neuritis, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, Child, Stroke, Mexico, Pandemics, Children, Myositis, Guillain-Barre syndrome, business.industry, SARS-CoV-2, Infant, Newborn, COVID-19, Infant, Anti-NMDA-R encephalitis, General Medicine, medicine.disease, Guillain-Barré syndrome, Child, Preschool, Acute cerebellar ataxia, Pediatrics, Perinatology and Child Health, Etiology, Original Article, Neurology (clinical), medicine.symptom, business, Rhabdomyolysis, 030217 neurology & neurosurgery, Encephalitis
Abstract: Purpose To describe the temporal association of specific acute neurological symptoms in pediatric patients with confirmed SARS-CoV-2 infection between May and August 2020. Methods We performed a recollection of all the clinical and laboratory data of patients having acute neurological symptoms temporally associated with SARS-CoV-2 infection at a third-level referral hospital in Mexico City (Instituto Nacional de Pediatría). Patients in an age group of 0–17 years with acute neurological signs (including ascending weakness with areflexia, diminished visual acuity, encephalopathy, ataxia, stroke, or weakness with plasma creatinine kinase (CK) elevation) were evaluated. Results Out of 23 patients with neurological manifestations, 10 (43%) had a confirmed SARS-CoV-2 infection. Among the infected patients, 5 (50%) were males aged 2–16 years old (median age 11.8 years old). Four (40%) patients confirmed a close contact with a relative positive for SARS-CoV-2, while 6 (60%) cases had a history of SARS-CoV-2–related symptoms over the previous 2 weeks. The following diagnoses were established: 3 cases of GBS, 2 of ON, 2 of AIS, one of myositis with rhabdomyolysis, one ACA, and one of anti-NMDA-R encephalitis. Conclusions Neurological manifestations temporally associated with SARS-CoV-2 infection were noticed in the pediatric population even without respiratory symptoms. In this study, 2 of 6 symptomatic patients had mild respiratory symptoms and 4 had unspecific symptoms. During this pandemic, SARS-CoV-2 infection should be considered as etiology in patients with acute neurological symptoms, with or without previous respiratory manifestations, particularly in teenagers.
Published: 2021

35. Applying data mining on customer relationship management system to discover forgotten effects

Author: Dra. Carolina Nicolas, Roberto Ahumada, Angélica Urrutia, and Fabiola Rojo
Subjects: Statistics and Probability, Knowledge management, Computer science, business.industry, General Engineering, 02 engineering and technology, Customer relationship management, 03 medical and health sciences, 0302 clinical medicine, Artificial Intelligence, 030221 ophthalmology & optometry, 0202 electrical engineering, electronic engineering, information engineering, 020201 artificial intelligence & image processing, business
Abstract: Companies need to know customer preferences for decision-making. For this reason, the companies take into account the Customer Relationship Management (CRM). These information systems have the objective to give support and allow the management of customer data. Nevertheless, it is possible to forget causal relationships that are not always explicit, obvious, or observables. The aim of this study on new methodologies for finding causal relationships. This research used a data analysis methodology of a CRM. The traditional analysis method is the Theory of Forgotten Effects (TFE), which is considered in this work. The new approach proposed in this article is to use Data Mining Algorithms (DMA) like Association Rules (AR) to discover causal relationships. This study analyzed 5,000 users’ comments and opinions about a Chilean foods industry company. The results show that the DMA used in this work obtains the same values as the TFE. Consequently, DMA can be used to identify non-obvious comments about products and services.
Published: 2021
Full Text: View/download PDF

36. Household pollution and COVID-19: irrelevant association?

Author: Marilyn Urrutia-Pereira, Carlos Augusto Mello-da-Silva, and Dirceu Solé
Subjects: Pulmonary and Respiratory Medicine, Pollution, medicine.medical_specialty, Isolation (health care), Working poor, Refugee, media_common.quotation_subject, Immunology, Disease, Heating, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Epidemiology, Pandemic, medicine, Humans, Immunology and Allergy, media_common, Transients and Migrants, Refugees, business.industry, Working Poor, COVID-19, General Medicine, Prognosis, Wood, Manure, Coal, Socioeconomic Factors, 030228 respiratory system, Air Pollution, Indoor, Etiology, Tobacco Smoke Pollution, business, 030215 immunology
Abstract: Evidence supports the link between air pollution and coronavirus disease 2019 (COVID-19). Therefore, exposure to indoor pollution (IDP) is likely to be associated with the disease. The poor, refugees, and migrant workers who live in feeble conditions are the most vulnerable. The pandemic has caused many people to remain indoors, especially at-risk individuals (e.g., the elderly, diabetics, obese, cardiac, and chronic lung disease patients). Home isolation may be an underlying factor to other health problems among these populations if the place where they are socially isolating is not adequately ventilated. Therefore, understanding the consequences of the relationship between IDP and the COVID-19 pandemic is essential.
Published: 2021
Full Text: View/download PDF

37. Multicriteria Methodology for Open Space Analysis

Author: Rufino Hernandez Minguillón, Olatz Grijalba Aseguinolaza, and Nagore Urrutia del Campo
Subjects: Urban Studies, business.industry, Computer science, Geography, Planning and Development, Environmental resource management, Space (commercial competition), business, Computer Science Applications, Diversity (business)
Abstract: This paper describes an urban analysis method for the evaluation of the diversity of open spaces. Diversity is understood as the variety of options that a public space offers to the users, giving them the opportunity to choose the area which best suits their needs, activities, and personal preferences. The method facilitates an environmental quality assessment and comparative evaluation between spaces. Decision support tools based on data analysis are developed to facilitate technical urban design decisions. The methodology is based on a multi-criteria analysis of a public square in Madrid, Spain. Field measurements of climatic data and thermal properties of materials, the activities carried out by people and their location, as well as factors related to urban design are collated in the analysis. Data are complimented with bioclimatic and simulation tools. The analysis identifies differentiated thermal profiles, as well as patterns of use of the space. This enables the identification of specific locations currently favored by citizens and the microclimatic and spatial variety of the square.
Published: 2021
Full Text: View/download PDF

38. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis

Author: Martínez Rivera, Carlos, Garcia-Olivé, Ignasi, Urrutia-Royo, Blanca, Basagaña-Torrento, Maria, Rosell, Antoni, Abad Capa, Jorge, and Universitat Autònoma de Barcelona
Subjects: Pulmonary and Respiratory Medicine, Budesonide, Male, medicine.medical_specialty, Pulmonary function, Exacerbation, Injections, Subcutaneous, Case Report, Churg-Strauss Syndrome, Antibodies, Monoclonal, Humanized, Gastroenterology, Bronchospasm, 03 medical and health sciences, chemistry.chemical_compound, Leukocyte Count, 0302 clinical medicine, Internal medicine, Forced Expiratory Volume, Eosinophilic, Medicine, Humans, Anti-Asthmatic Agents, Asthma, lcsh:RC705-779, business.industry, Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis, Granulomatosis with Polyangiitis, 030208 emergency & critical care medicine, Benralizumab, lcsh:Diseases of the respiratory system, Eosinophil, Middle Aged, respiratory system, medicine.disease, respiratory tract diseases, Eosinophils, medicine.anatomical_structure, Treatment Outcome, 030228 respiratory system, chemistry, Disease Progression, medicine.symptom, business, Granulomatosis with polyangiitis, medicine.drug
Abstract: Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a disease that is associated with severe uncontrolled eosinophilic asthma. Eosinophils play an important pathogenic role in the development of both diseases. Benralizumab is an antieosinophilic monoclonal antibody that binds to the α subunit of the human interleukin 5 receptor that is expressed on the surface of the eosinophil and basophil. We present the first case of rapid improvement in symptoms and lung function during admission for exacerbation of a severe eosinophilic asthma associated with EGPA. Case presentation A 57-year-old man diagnosed with severe eosinophilic asthma associated to EGPA was admitted to the Pulmonology Department due to severe bronchospasm. At admission he presented 2300 eosinophils/µl. Despite intensive bronchodilator treatment, intravenous methylprednisolone at a dose of 80 mg/d, oxygen therapy, and budesonide nebulization, the patient continued to present daily episodes of bronchospasm. Ten days after admission, with blood eosinophil levels of 1700 cells/µl, benralizumab 30 mg sc was administered. That day, the Forced Expiratory Volume in the first second (FEV1) was 28% of the theoretical value (1150 ml). AT three days, FEV1 increased to 110 ml (31%). On the 9th day FEV1 was 51% (2100 ml). The blood eosinophil level on the 9th day was 0 cells/µl. Conclusions The rapid improvement of FEV1 is in line with studies based on clinical trials that found improvement after two days in peak flow and one phase II study that showed rapid response in exacerbation of asthma in the emergency room. The antieosinophilic effect at 24 h and the effect in different tissues determine the rapid improvement and the potential advantage of benralizumab in the treatment of EGPA. This case suggests the usefulness of benralizumab in patients with EGPA and eosinophilic severe asthma who show bronchospasm refractory to conventional treatment during a hospitalization due to asthma exacerbation.
Published: 2021

39. The new AO classification system for intertrochanteric fractures allows better agreement than the original AO classification. An inter- and intra-observer agreement evaluation

Author: Pablo Besa, Daniel Schweitzer, Ianiv Klaber, Daniel Lobos, Felipe Sandoval, Julio Urrutia, and Tomas Zamora
Subjects: Observer Variation, 030222 orthopedics, Hip Fractures, business.industry, Reproducibility of Results, 030208 emergency & critical care medicine, Intra observer, Radiography, 03 medical and health sciences, Orthopedics, 0302 clinical medicine, Cohen's kappa, Statistics, Humans, General Earth and Planetary Sciences, Medicine, Ao classification, business, General Environmental Science
Abstract: Background A new AO classification for intertrochanteric fractures was recently published; no studies have evaluated its inter- and intra-observer agreement. Methods Six evaluators (three hip subspecialists and three residents) assessed radiographs of 68 intertrochanteric fractures; fractures were classified using the original and the new AO classifications. The cases were displayed in a random sequence after a six-week interval for repeat evaluation. We used the Kappa coefficient (k) to determine inter- and intra-observer agreement. Results Inter-observer agreement was slight (k = 0.128 [0.092–0.170]) using the original and fair (k = 0.250 [0.186–0.327]), with the new AO classification. Orthopedic residents exhibited better agreement than hip surgeons using the original classification (k = 0.302 [0.210–0.416] and k= -0.018 [-0.058–0.029], respectively) and the new classification (k = 0.388 [0.294–0.514] and k = 0.109 [0.031–0.192], respectively). Using both classifications as dichotomous variables (stable or unstable patterns), the agreement was slight (k = 0.158 [0.074–0.246]) using the original classification and moderate (k = 0.425 [0.308–0.550]) with the new AO classification. Intra-observer The agreement was fair using the original (k = 0.350 [0.278–0.424]) and the new (k = 0.295 [0.239 to 0.353]) AO classifications, respectively. Residents had better agreement than hip specialists using the original (k = 0.405 [0.303–0.512]) versus (k = 0.292 [0.193–0.293]) and the new classification (k = 0.449 [0.370 to 0.528] versus k = 0.129 [0.064 to 0.208]). Conclusion The inter-observer agreement using the new AO classification was significantly better than using its original version. Also, the new AO classification system allowed better agreement when distinguishing stable from unstable patterns.
Published: 2021
Full Text: View/download PDF

40. Implementing living evidence to inform health decisions: A strategy for building capacity in health sector (Protocol)

Author: Ariadna Auladell-Rispau, David Rigau, Gerard Urrutia Chuchí, Pablo Alonso, María Ximena Rojas-Reyes, and Gabriel Rada
Subjects: health decisions, Process management, Process (engineering), Psychological intervention, 030204 cardiovascular system & hematology, decision making, 03 medical and health sciences, Study Protocol, 0302 clinical medicine, Brainstorming, heath systems research, Health care, living evidence framework, 030212 general & internal medicine, Protocol (science), business.industry, capacity building, Capacity building, living evidence, evidence synthesis, General Medicine, Best value, Articles, knowledge transfer, 3. Good health, business, Knowledge transfer
Abstract: Every day important healthcare decisions are made with incomplete or outdated information about the effects of the different health care interventions available, what delivers the best value for the health system and where more research is needed. It is necessary to invest in strategies that allow access to reliable and updated evidence on which to base health decisions. The objective is to develop and evaluate a strategy for building the capacity among different actors of a country’s health system to implement the model known as “Living Evidence” [LE] in the evidence synthesis and dissemination of knowledge transfer [KT] products to inform health decisions. The study will involve professional members of health system organizations in charge of developing KT-products to inform health decisions. The project will be developed in three complementary phases: 1) LE-implementation framework development through review of the literature, brainstorming meetings, user testing and expert consultation; 2) training in LE tools and strategies; 3) developing LE synthesis for KT-products by applying the framework to real-life diverse situations. To achieve the capacity building strategy assessment goal, several surveys and interviews will take place during the process to assess: 1) the LE-implementation framework for the incorporation of LE synthesis in the development of KT-products; 2) the training workshops; 3) the whole capacity-building strategy used for health system organizations be able of implementing the LE as part of the KT-products they regularly produce. The expected results are an effective capacity building strategy for health system organizations to implement the living evidence model in different KT products; a LE-implementation framework to be applicable to any country or region for incorporate LE in the KT-products; LE synthesis for KT-products directly applicable to the real-setting situations; integration of Epistemonikos-L.OVE platform for keeping the LE process in the development and updating of KT-products.
Published: 2022
Full Text: View/download PDF

41. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

Author: Bédard, Annabelle, Antó, Josep, Fonseca, Joao, Arnavielhe, Sylvie, Bachert, Claus, Bedbrook, Anna, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Cardona, Victoria, Cruz, Alvaro, Fokkens, Wytske, Garcia-Aymerich, Judith, Hellings, Peter, Ivancevich, Juan, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée, Melen, Erik, Monti, Ricardo, Mösges, Ralf, Mullol, Joaquim, Papadopoulos, Nikos, Pham-Thi, Nhan, Samolinski, Boleslaw, V Tomazic, Peter, Toppila-Salmi, Sanna, Ventura, Maria Teresa, Yorgancioglu, Arzu, Bousquet, Jean, Pfaar, Oliver, Basagana, Xavier, Bosnic‐Anticevich, Sinthia, Pham‐Thi, Nhân, Hellings, PW, Aberer, W., Agache, I., Akdis, Ca, Akdis, M., Aliberti, MR, Almeida, R., Amat, F., Angles, R, Annesi‐Maesano, I, Ansotegui, IJ, Anto, JM, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiardini, I, Barbara, C, Barbagallo, M., Baroni, I, Barreto, BA, Basagaña, X., Bateman, ED, Bedolla‐Barajas, M, Bewick, M., Beghé, B., Bel, EH, Bergmann, KC, Bennoor, KS, Benson, M, Bertorello, L, Białoszewski, AZ, Bieber, T., Bialek, S, Bindslev‐Jensen, Carsten, Bjermer, L., Blain, H., Blasi, F., Blua, A, Bochenska Marciniak, M, Bogus‐Buczynska, I, Boner, AL, Bonini, M., Bonini, S., Bosnic‐Anticevich, CS, Bosse, I., Bouchard, J., Boulet, LP, Bourret, R., Bousquet, Pj, Braido, F, Briedis, V, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Burguete Cabañas, MT, Burte, E., Bush, A, Caballero‐Fonseca, F, Caillaud, D., Caimmi, D., Calderon, MA, Camargos, PAM, Camuzat, T., Canfora, G, Canonica, Gw, Carlsen, KH, Carreiro‐Martins, P, Carriazo, AM, Carr, W, Cartier, C., Casale, T., Castellano, G, Cecchi, L, Cepeda, AM, Chavannes, NH, Chen, Y., Chiron, R., Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Cingi, C, Ciprandi, G, Carvalho Coehlo, AC, Colas, L, Colgan, E, Coll, J, Conforti, D, Constantinidis, J, de Sousa, J Correia, Cortés‐Grimaldo, RM, Corti, F, Costa, E, Costa‐Dominguez, MC, Courbis, AL, Cox, L, Crescenzo, M, Cruz, AA, Custovic, A., Czarlewski, W., Dahlen, Se, D’Amato, G, Dario, C, Da Silva, J., Dauvilliers, Y., Darsow, U, De Blay, F., De Carlo, G, Dedeu, T, de Fátima Emerson, M, De Feo, G., De Vries, G, De Martino, B, Motta Rubini, NP, Deleanu, D, Denburg, JA, devillier, P., Di Capua Ercolano, S, Di Carluccio, N, Didier, A., Dokic, D, Dominguez‐Silva, MG, Douagui, H, Dray, G., Dubakiene, R, Durham, Sr, Du Toit, G, Dykewicz, MS, El‐Gamal, Y, Eklund, P, Eller, E, Emuzyte, R., Farrell, J, Farsi, A, de Mello, J Ferreira, Ferrero, J, Fink‐Wagner, A, Fiocchi, A, Fokkens, WJ, Fonseca, JA, Fontaine, Jf, Forti, S, Fuentes‐Perez, JM, Gálvez‐Romero, JL, Gamkrelidze, A, Garcia‐Aymerich, Judith, García‐Cobas, CY, Garcia‐Cruz, MH, Gemicioğlu, B, Genova, S, Christoff, G, Gereda, JE, Van Wijk, R Gerth, Gomez, RM, Gómez‐Vera, J, González Diaz, S, Gotua, M., Grisle, I, Guidacci, M, Guldemond, NA, Gutter, Z, Guzmán, MA, Haahtela, T., Hajjam, J, Hernández, L, Hourihane, JO’B, Huerta‐Villalobos, YR, Humbert, M., Iaccarino, G., Illario, M, Ispayeva, Z, Ivancevich, JC, Jares, EJ, Jassem, E, Johnston, Sl, Joos, G, Jung, KS, Just, J., Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keil, T, Keith, PK, Khaitov, M, Khaltaev, N, Kleine‐Tebbe, J, Kowalski, Ml, Kuitunen, M, Kull, I., Kupczyk, M, Krzych‐Fałta, E, Lacwik, P, Larenas‐Linnemann, Désirée, Laune, D., Lauri, D, Lavrut, J, Le, LTT, Lessa, M, Levato, G, Li, J., Lieberman, P, Lipiec, A, Lipworth, B, Lodrup Carlsen, KC, Louis, R, Lourenço, O, Luna‐Pech, JA, Magnan, A., Mahboub, B, Maier, D., Mair, A, Majer, I, Malva, J, Mandajieva, E, Manning, P, De Manuel Keenoy, E, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu‐Dupas, E, Matta Campos, JJ, Matos, AL, Maurer, M, Mavale‐Manuel, S, Mayora, O, Meco, C, Medina‐Avalos, MA, Melo‐Gomes, E, Meltzer, EO, Menditto, E., Miculinic, N, Mihaltan, F., Milenkovic, B, Moda, G, Mogica‐Martinez, MD, Mohammad, Y, Momas, I., Montefort, S, Mora Bogado, D, Morais‐Almeida, M, Morato‐Castro, FF, Mota‐Pinto, A, Moura Santo, P, Münter, L, Muraro, A, Murray, R, Naclerio, R., Nadif, R., Nalin, M, Napoli, L, Namazova‐Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira‐Silva, L, Nogues, M., Novellino, E, Nyembue, TD, O’Hehir, RE, Odzhakova, C, Ohta, K., Okamoto, Y., Okubo, K, Onorato, GL, Ortega Cisneros, M, Ouédraogo, S., Pali‐Schöll, I, Palkonen, S, Panzner, P, Papadopoulos, NG, Park, HS, Papi, A., Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pépin, JL, Pereira, AM, Persico, M, PHILLIPS, J, Picard, R., Pigearias, B, Pin, I., Pitsios, C., Plavec, D, Pohl, W, Popov, TA, Portejoie, F., Potter, P, Pozzi, AC, Price, D, Prokopakis, EP, Puy, R, Pugin, B, Pulido Ross, RE, Przemecka, M, Rabe, KF, Raciborski, F, Rajabian‐Soderlund, R, Reitsma, S, Ribeirinho, I, Rimmer, J, Rivero‐Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo‐Cordeiro, C, Rodenas, F, Rodo, X, Rodriguez Gonzalez, M, Rodriguez‐Mañas, L, Rolland, C, Rodrigues Valle, S, Roman Rodriguez, M., Romano, A, Rodriguez‐Zagal, E, Rolla, G, Roller‐Wirnsberger, RE, Romano, M, Rosado‐Pinto, J, Rosario, N., Rottem, M, Ryan, D, Sagara, H, Salimäki, J, Sanchez‐Borges, M, Sastre‐Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid‐Grendelmeier, P, Sarquis Serpa, F, Shamai, S., Sheikh, A., Sierra, M, Simons, FER, Siroux, V., Sisul, JC, Skrindo, I, Solé, D, Somekh, D, Sondermann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stellato, C, Stelmach, R, Stukas, R, Sunyer, J., Strozek, J, Szylling, A, Tebyriçá, JN, Thibaudon, M., To, T., Todo‐Bom, A, Tomazic, PV, Toppila‐Salmi, Sanna, Trama, U, Triggiani, M, Suppli Ulrik, C, Urrutia‐Pereira, M, Valenta, R, Valero, A., Valiulis, A., Valovirta, E., van Eerd, M, Van Ganse, E., van Hage, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A., Verissimo, MT, Viart, F., Viegi, G., Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S., Werfel, T, Westman, M, Wickman, M., Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yusuf, OM, Zar, HJ, Zhang, L., Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zuberbier, T., Zubrinich, C, Zurkuhlen, A, Mercier, Jacques, Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), IMIM-Hospital del Mar, Generalitat de Catalunya, Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, KYomed INNOV, Ghent University Hospital, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Odense University Hospital [Odense, Denmark], Woolcock Institute of Medical Research [Sydney], The University of Sydney, Vall d'Hebron University Hospital [Barcelona], ProAR - FMB, Federal University of Bahia School of Medicine, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), University Hospitals Leuven [Leuven], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Vilnius University [Vilnius], Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris] (IP), Medical University of Warsaw - Poland, Department of Pulmonology, Manisa Celal Bayar University, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Aix Marseille Université (AMU), Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), iQ4U consultants Ltd, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Department of Respiratory Medicine and Allergy, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, CHU Montpellier, Laboratoire National Henri Becquerel (LNHB), Département Métrologie Instrumentation & Information (DM2I), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Département d'instrumentation Numérique (DIN (CEA-LIST)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Région Languedoc-Roussillon-Midi-Pyrénées, University of South Florida [Tampa] (USF), Chinese academy of sciences Sanya, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Department of Paediatrics, UCB Pharma, Colombes, CHU Strasbourg, Università degli Studi di Salerno = University of Salerno (UNISA), Hôpital Foch [Suresnes], Service de pneumologie [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Informatique, Image, Intelligence Artificielle (I3A), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IMT - MINES ALES (IMT - MINES ALES), Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Center for Turbulence Research [Stanford] (CTR), Stanford University, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Biomax Informatics AG, 'Federico II' University of Naples Medical School, Pneumology Department, Marius Nasta Institute of Pneumology, Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Johns Hopkins University School of Medicine [Baltimore], CARSAT-LR, Montpellier, Dept. of Electronic Engineering, Chubu University, Institute for Solid State Physics, The University of Tokyo (UTokyo), Respiratory Medicine, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, University of Cyprus [Nicosia] (UCY), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Réseau National de Surveillance Aérobiologique (RNSA), CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, University of Turku, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), ASA (Advanced Solution Accelerator) (Data management : Développement Back-Office, hébergement…), 34830 Jacou, Consiglio nazionale delle ricerche, Instituto di fisiologia clinica, McMaster University [Hamilton, Ontario], Department of Molecular Medicine and Surgery, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), University Hospital of Cologne [Cologne], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), ISGlobal, Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Porto, Portugal, KYomed INNOV, Montpellier, France, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, MACVIA-France, Montpellier, France, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, Euforea, Brussels, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino & Mauriziano Hospital, Torino, Italy, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, Pasteur Institute, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Department of General ORL, H&NS, Medical University of Graz, Graz, Austria, Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, University Hospital, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany, Universidade do Porto, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pasteur [Paris], University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Università degli Studi di Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, University of Helsinki, Service d'Allergologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Cyprus [Nicosia], Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Bedard, A., Anto, J. M., Fonseca, J. A., Arnavielhe, S., Bachert, C., Bedbrook, A., Bindslev-Jensen, C., Bosnic-Anticevich, S., Cardona, V., Cruz, A. A., Fokkens, W. J., Garcia-Aymerich, J., Hellings, P. W., Ivancevich, J. C., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linnemann, D., Melen, E., Monti, R., Mosges, R., Mullol, J., Papadopoulos, N. G., Pham-Thi, N., Samolinski, B., Tomazic, P. V., Toppila-Salmi, S., Ventura, M. T., Yorgancioglu, A., Bousquet, J., Pfaar, O., Basagana, X., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Aliberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Bateman, E. D., Bedolla-Barajas, M., Bewick, M., Beghe, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Bialoszewski, A. Z., Bieber, T., Bialek, S., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabanas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillaud, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Constantinidis, J., Correia de Sousa, J., Cortes-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Custovic, A., Czarlewski, W., Dahlen, S. E., D'Amato, G., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fatima Emerson, M., De Feo, G., De Vries, G., De Martino, B., Motta Rubini, N. P., Deleanu, D., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Galvez-Romero, J. L., Gamkrelidze, A., Garcia-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioglu, B., Genova, S., Christoff, G., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gomez-Vera, J., Gonzalez Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzman, M. A., Haahtela, T., Hajjam, J., Hernandez, L., Hourihane, J. O. '. B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ispayeva, Z., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Just, J., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M. L., Kuitunen, M., Kull, I., Kupczyk, M., Krzych-Falta, E., Lacwik, P., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenco, O., Luna-Pech, J. A., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Meco, C., Medina-Avalos, M. A., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mota-Pinto, A., Moura Santo, P., Munter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Scholl, I., Palkonen, S., Panzner, P., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pepin, J. L., Pereira, A. M., Persico, M., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Manas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimaki, J., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Sarquis Serpa, F., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Sole, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyrica, J. N., Thibaudon, M., To, T., Todo-Bom, A., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hage, M., Vandenplas, O., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, G., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zhanat, I., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Universidade do Porto [Porto], Kyomed, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universitat Pompeu Fabra [Barcelona], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Dermatology [Graz, Austria], Medical University Graz, University of Zürich [Zürich] (UZH), National Institute for Nuclear Physics (INFN), Institut Jean Lamour (IJL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Clermont Université-Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Recherche Agronomique (INRA), University of South Florida (USF), University of Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey, Institut Mines-Télécom [Paris] (IMT), Center for Turbulence Research (CTR), Stanford University [Stanford], Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), The University of Tokyo, Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), RNSA, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bedard A., Anto J.M., Fonseca J.A., Arnavielhe S., Bachert C., Bedbrook A., Bindslev-Jensen C., Bosnic-Anticevich S., Cardona V., Cruz A.A., Fokkens W.J., Garcia-Aymerich J., Hellings P.W., Ivancevich J.C., Klimek L., Kuna P., Kvedariene V., Larenas-Linnemann D., Melen E., Monti R., Mosges R., Mullol J., Papadopoulos N.G., Pham-Thi N., Samolinski B., Tomazic P.V., Toppila-Salmi S., Ventura M.T., Yorgancioglu A., Bousquet J., Pfaar O., Basagana X., Aberer W., Agache I., Akdis C.A., Akdis M., Aliberti M.R., Almeida R., Amat F., Angles R., Annesi-Maesano I., Ansotegui I.J., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Bateman E.D., Bedolla-Barajas M., Bewick M., Beghe B., Bel E.H., Bergmann K.C., Bennoor K.S., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bosse I., Bouchard J., Boulet L.P., Bourret R., Bousquet P.J., Braido F., Briedis V., Brightling C.E., Brozek J., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillaud D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Canonica G.W., Carlsen K.H., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Casale T., Castellano G., Cecchi L., Cepeda A.M., Chavannes N.H., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Constantinidis J., Correia de Sousa J., Cortes-Grimaldo R.M., Corti F., Costa E., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Czarlewski W., Dahlen S.E., D'Amato G., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., De Carlo G., Dedeu T., de Fatima Emerson M., De Feo G., De Vries G., De Martino B., Motta Rubini N.P., Deleanu D., Denburg J.A., Devillier P., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Dykewicz M.S., El-Gamal Y., Eklund P., Eller E., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Fontaine J.F., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., Christoff G., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Guzman M.A., Haahtela T., Hajjam J., Hernandez L., Hourihane J.O.'.B., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Illario M., Ispayeva Z., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Just J., Jutel M., Kaidashev I., Kalayci O., Kalyoncu A.F., Karjalainen J., Kardas P., Keil T., Keith P.K., Khaitov M., Khaltaev N., Kleine-Tebbe J., Kowalski M.L., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Laune D., Lauri D., Lavrut J., Le L.T.T., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Lourenco O., Luna-Pech J.A., Magnan A., Mahboub B., Maier D., Mair A., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Meco C., Medina-Avalos M.A., Melo-Gomes E., Meltzer E.O., Menditto E., Mercier J., Miculinic N., Mihaltan F., Milenkovic B., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Mora Bogado D., Morais-Almeida M., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Murray R., Naclerio R., Nadif R., Nalin M., Napoli L., Namazova-Baranova L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Novellino E., Nyembue T.D., O'Hehir R.E., Odzhakova C., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Palkonen S., Panzner P., Park H.S., Papi A., Passalacqua G., Paulino E., Pawankar R., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Plavec D., Pohl W., Popov T.A., Portejoie F., Potter P., Pozzi A.C., Price D., Prokopakis E.P., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Rajabian-Soderlund R., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Rottem M., Ryan D., Sagara H., Salimaki J., Sanchez-Borges M., Sastre-Dominguez J., Scadding G.K., Schunemann H.J., Scichilone N., Schmid-Grendelmeier P., Sarquis Serpa F., Shamai S., Sheikh A., Sierra M., Simons F.E.R., Siroux V., Sisul J.C., Skrindo I., Sole D., Somekh D., Sondermann M., Sooronbaev T., Sova M., Sorensen M., Sorlini M., Spranger O., Stellato C., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., To T., Todo-Bom A., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., Valero A., Valiulis A., Valovirta E., van Eerd M., van Ganse E., van Hage M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi G., Vicheva D., Vontetsianos T., Wagenmann M., Walker S., Wallace D., Wang D.Y., Waserman S., Werfel T., Westman M., Wickman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zhang L., Zhong N., Zernotti M.E., Zhanat I., Zidarn M., Zuberbier T., Zubrinich C., and Zurkuhlen A.
Subjects: 0301 basic medicine, SYMPTOMS, Smart phone, Allergy, Escala visual analógica, INNOVATION, [SDV]Life Sciences [q-bio], Medical and Health Sciences, Correlation, visual analogue scale, 0302 clinical medicine, Quality of life, Visual analogue scale, QUALITY-OF-LIFE, Màscares, Immunology and Allergy, score, Nose, Rinitis, Rhinitis, PRODUCTIVITY COSTS, asthma, MASK, rhinitis, Score, Explained variation, Response Variability, Mobile Applications, ALLERGIC RHINITIS, rhiniti, medicine.anatomical_structure, TRIALS, Rinite, 1107 Immunology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Smartphone, medicine.medical_specialty, MASK study group, Immunology, MACVIA-ARIA, 03 medical and health sciences, Allergic, medicine, Humans, TECHNOLOGY, IMMUNOTHERAPY, Asma, Asthma, business.industry, Rhinitis, Allergic, medicine.disease, RHINOCONJUNCTIVITIS, 030104 developmental biology, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, Physical therapy, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Published: 2020
Full Text: View/download PDF

42. Radical nephrectomy: three surgical approaches, one surgeon, at the National Institute of Neoplastic Diseases, Lima - Perú, 2014-2020

Author: Oscar Rubén Chapoñán-Sipión, Enrique Franco-Rojas, Luis Alberto Cohaila-Ramos, Luis Taxa-Rojas, Aníbal Carranza-Bedoya, Víctor Destéfano-Urrutia, Gilmer Arcenio Díaz-Pérez, Nepton Víctor David Ruiz-Aguilar, and Javier Renato Marquillo-Romero
Subjects: Marketing, Pharmacology, Organizational Behavior and Human Resource Management, medicine.medical_specialty, Surgical approach, business.industry, Strategy and Management, General surgery, medicine.medical_treatment, Pharmaceutical Science, Nephrectomy, Drug Discovery, medicine, business
Published: 2020
Full Text: View/download PDF

43. The Effect of Sleep Apnea on Cardiovascular Events in Different Acute Coronary Syndrome Phenotypes

Author: Andrea Zapater, Manuel Sánchez-de-la-Torre, Ivan David Benítez, Adriano Targa, Sandra Bertran, Gerard Torres, Albina Aldomà, Jordi De Batlle, Jorge Abad, Joaquín Duran-Cantolla, Valentin Cabriada-Nuño, Olga Mediano, María José Masdeu, Carmen Muñoz, Juan Fernando Masa, Mónica De la Peña, Mercè Mayos, Ramon Coloma, Josep María Montserrat, Eusebi Chiner, Olga Mínguez, Lydia Pascual, Anunciación Cortijo, Dolores Martínez, Mireia Dalmases, R. Doug McEvoy, Ferran Barbé, Alicia Sánchez-de-la-Torre, Laura Abad, Aida Muñoz, Elisabet Zamora, Ignacio Vicente, Sandra Inglés, Carlos Egea, Jaime Marcos, Almudena Fernández, Chechu Amibilia, Amaia Urrutia, Sonia Castro, Leyre Serrano, Marina Florés, Estefanía Galera, Anna Mas, Montserrat Martínez, Maricel Arbonés, Silvia Ortega, Alicia Martín, Jose Miguel Román-Sánchez, Mª Isabel Valiente-Diaz, Mª Esther Viejo-Ayuso, Concepción Rodríguez-García, Laura Vigil, Enriqueta Ramírez, María Piñar, Elisabet Martínez, Estrella Ordax, Blanca Barriuso, Jaime Corral, Francisco Javier Gómez de Terreros Caro, Antonia Barceló, Paloma Giménez, Miguel Carrera, Ana Mª Fortuna, Patricia Peñacoba, Abel Jesús Martínez García, Sergio García Castillo, Lara Navas, Onintza Garmendia, José Sancho, Salvador Perelló, and Gemma Rubinós
Subjects: Pulmonary and Respiratory Medicine, Acute coronary syndrome, medicine.medical_specialty, business.industry, Sleep apnea, Disease, Critical Care and Intensive Care Medicine, medicine.disease, Precision medicine, nervous system diseases, respiratory tract diseases, Obstructive sleep apnea, 03 medical and health sciences, 0302 clinical medicine, stomatognathic system, 030228 respiratory system, Internal medicine, medicine, Cardiology, In patient, 030212 general & internal medicine, business
Abstract: Rationale: Obstructive sleep apnea (OSA) is associated with increased cardiovascular disease (CVD) risk. Conversely, OSA has not been shown to increase recurrent cardiovascular events in patients w...
Published: 2020
Full Text: View/download PDF

44. Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial

Author: Guillermo E. Umpierrez, Robert A. Guyton, Maya Fayfman, Saumeth Cardona, Sol Jacobs, Francisco J. Pasquel, Limin Peng, Priyathama Vellanki, Maria A. Urrutia, Georgia Davis, W. Brent Keeling, Alexandra Migdal, Bonnie S. Albury, Katerina Tsegka, Steven K. Macheers, Michael E. Halkos, and Rodolfo J. Galindo
Subjects: Adult, Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Article, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, Cardiac Surgical Procedures, Aged, business.industry, Insulin, Sitagliptin Phosphate, Perioperative, Middle Aged, medicine.disease, Intensive care unit, Cardiac surgery, Treatment Outcome, Diabetes Mellitus, Type 2, Hyperglycemia, Sitagliptin, Anesthesia, business, medicine.drug
Abstract: Background Hyperglycaemia is associated with increased incidence of perioperative complications. We assessed whether treatment with sitagliptin, starting before surgery and continued during the hospital stay, can prevent and reduce the severity of perioperative hyperglycaemia in patients with type 2 diabetes undergoing coronary artery bypass graft (CABG) surgery. Martials and methods We conducted a double-blinded, placebo-control trial in adults with type 2 diabetes randomly assigned to receive sitagliptin or matching placebo starting one day prior to surgery and continued during the hospital stay. The primary outcome was difference in the proportion of patients with postoperative hyperglycaemia (blood glucose [BG] >10mmol/L [>180mg/dL]) in the intensive care unit (ICU). Secondary endpoints included differences in mean daily BG in the ICU and after transition to regular wards, hypoglycaemia, hospital complications, length of stay, and need of insulin therapy. Results We included 182 participants randomised to receive sitagliptin or placebo (91 per group, age 64±9 years, HbA1C: 7∙6±1∙5%, and diabetes duration: 10±9 years). There were no differences in number of patients with postoperative BG >10 mmol/L, mean daily BG in the ICU or after transition to regular floors, hypoglycaemia, hospital complications or length of stay. There were no differences on insulin requirements in the ICU; however, sitagliptin therapy was associated with lower mean daily insulin requirements (21∙1±18∙4 vs 32∙5±26∙3 units, p=0∙007) after transition to regular floor compared to placebo. Conclusion The administration of sitagliptin prior to surgery and during the hospital stay, did not prevent perioperative hyperglycaemia or complications after CABG. Sitagliptin therapy was associated with lower mean daily insulin requirements after transition to regular floors. This article is protected by copyright. All rights reserved.
Published: 2020
Full Text: View/download PDF

45. Vascular imaging in the initial evaluation of embolic stroke source

Author: Joseph H. Huntley, Jina Pakpoor, Victor C. Urrutia, Oluwatoyin R. Idowu, David M. Yousem, Sadaf Sahraian, Majid K. Khan, and Elham Beheshtian
Subjects: medicine.medical_specialty, Brain Ischemia, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Carotid Stenosis, Radiology, Nuclear Medicine and imaging, cardiovascular diseases, Stroke, Retrospective Studies, Vascular imaging, business.industry, Incidence (epidemiology), Neurovascular bundle, medicine.disease, Embolic stroke, Stenosis, 030220 oncology & carcinogenesis, cardiovascular system, Etiology, Radiology, Tomography, X-Ray Computed, business, Vascular Stenosis, Magnetic Resonance Angiography
Abstract: Purpose During acute ischemic stroke evaluations, neurovascular imaging is commonly performed to localize the source of a thromboembolus and to identify vascular stenoses. In this study, we aimed to analyze 1) the usefulness of intracranial and/or cervical CTA and MRA and carotid doppler ultrasound (DUS) for identifying the stroke source and 2) the incidence of vascular stenoses across stroke etiologies. Methods We retrospectively reviewed intracranial and/or cervical CTA, DUS and MRA studies to identify the source of the acute stroke by Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria for 200 consecutive patients admitted with a stroke to our tertiary hospital. Stroke etiologies were ascertained and the rates of intracranial and cervical vascular stenoses were stratified by stroke type. Results Of 200 patients, the most probable sources of stroke were small vessel disease (29%), cardioembolic (26.0%) and atheroembolic (23.5%). Across all groups, 27.5% of patients had ≥70% stenosis on neurovascular imaging. The rate of ≥70% vascular stenosis in the neck was 6.9% and 5.8% in the small vessel and cardioembolic categories, respectively. Conclusions The TOAST etiologies of strokes were nearly equally distributed. Neurovascular imaging was of high utility for identifying large vessel intracranial stenoses in patients presenting with acute stroke across all etiologies, although neck CTA/MRA had a lower rate of positive studies with cardiogenic and small vessel strokes. These findings have implications on the use of CTA/MRA in acute stroke work-up.
Published: 2020
Full Text: View/download PDF

46. Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers

Author: Gwen Lomberk, Pardeep Mittal, Michelle D. Reid, Bassel F. El-Rayes, Shishir K. Maithel, Burcin Pehlivanoglu, Kathleen K. Christians, Jeanette D. Cheng, Douglas B. Evans, Kenneth Cardona, Susan Tsai, Raul Urrutia, Yue Xue, Juan M. Sarmiento, Aarti Sekhar, Volkan Adsay, David A. Kooby, Bahar Memis, Kee Taek Jang, Raul S. Gonzalez, and Takashi Muraki
Subjects: Ampulla of Vater, Pathology, medicine.medical_specialty, Common Bile Duct Neoplasms, Peri, Early detection, 03 medical and health sciences, 0302 clinical medicine, Duodenal Neoplasms, medicine, Pancreatic border, Humans, Hepatology, business.industry, Gastroenterology, Pancreatic Neoplasms, Bile Ducts, Intrahepatic, medicine.anatomical_structure, Bile Duct Neoplasms, Common hepatic duct, 030220 oncology & carcinogenesis, Cystic duct, 030211 gastroenterology & hepatology, Pancreas Cancers, Pancreas, business
Abstract: The cause of most pancreatic and periampullary cancers (PAC) is unknown. Recently, anatomic variations such as pancreatobiliary maljunction have been recognized as risk factors, similar to Barrett-related gastro-esophageal cancers.Pre-operative MRI from 860 pancreatic/biliary resections, including 322 PACs, were evaluated for low-union (cystic duct joining the common hepatic duct inside of the pancreas or within 5 mm of the pancreatic border) RESULTS: Low-union, seen10% of the population, was present in 44% of PACs (73% distal bile duct/cholangiocarcinoma, 42% pancreatic head, and 34% ampullary). It was significantly lower(11%) in conditions without connection to the ductal system (thus not exposed to the ductal/biliary tract contents), namely mucinous cystic neoplasms and intrahepatic cholangiocarcinomas(p0.0001). Intra-pancreatic type low-union was seen in 16% of PACs versus 2% of controls(p0.0001).This study establishes an association between low-union and PACs, and points to an anatomy-induced chemical/bilious carcinogenesis. This may explain why most pancreas cancers are in the head. It is possible that the same chemical milieu, caused by conditions other than low-union/insertion, may also play a role in the remaining half of PACs. This opens various treatment opportunities including milieu modifications (chemoprevention), focused screening of at-risk patients, and early detection with possible corrective actions.
Published: 2020
Full Text: View/download PDF

47. Ontology-based Data Management Tool for Studying Radon Concentration

Author: F´elix Fern´andez-Pe˜na, Alex Maigua-Quinteros, Pilar Urrutia-Urrutia, and Diana Coello-Fiallos
Subjects: Information retrieval, Physics and Astronomy (miscellaneous), chemistry, business.industry, Computer science, Management of Technology and Innovation, Data management, chemistry.chemical_element, Radon, Ontology (information science), business, Engineering (miscellaneous)
Published: 2020
Full Text: View/download PDF

48. Production of moth sex pheromones for pest control by yeast fermentation

Author: Bruno Sommer Ferreira, William H. Urrutia, Lucas Martins França, Marie Inger Dam, Kanchana Rueksomtawin Kildegaard, Bao-Jian Ding, Karolis Petkevicius, Bettina Lorantfy, Marina Pires, Carmem R. Bernardi, Hong-Lei Wang, Eleni Koutsoumpeli, Dimitris Raptopoulos, Irina Borodina, Maria Konstantopoulou, Christina Sinkwitz, Agenor Mafra-Neto, Leonie Wenning, Christer Löfstedt, and Carina Holkenbrink
Subjects: Yarrowia lipolytica, Male, 0106 biological sciences, Fatty actyl-CoA desaturase, Mating disruption, media_common.quotation_subject, Yarrowia, Bioengineering, Insect, Moths, Biology, Helicoverpa armigera, 01 natural sciences, Applied Microbiology and Biotechnology, 03 medical and health sciences, SDG 3 - Good Health and Well-being, 010608 biotechnology, Animals, Humans, Food science, Sex Attractants, 030304 developmental biology, media_common, Fatty alcohols, 0303 health sciences, business.industry, fungi, Pest control, biology.organism_classification, Yeast, Lepidoptera, 010602 entomology, Sex pheromone, Fermentation, Pheromone, Pest Control, business, Biotechnology
Abstract: The use of insect sex pheromones is an alternative technology for pest control in agriculture and forestry, which, in contrast to insecticides, does not have adverse effects on human health or environment and is efficient also against insecticide-resistant insect populations.1,2 Due to the high cost of chemically synthesized pheromones, mating disruption applications are currently primarily targeting higher value crops, such as fruits.3 Here we demonstrate a biotechnological method for the production of pheromones of economically important moth pests using engineered yeast cell factories. Biosynthetic pathways towards several pheromones or their precursors were reconstructed in the oleaginous yeast Yarrowia lipolytica, which was further metabolically engineered for improved pheromone biosynthesis by decreasing fatty alcohol degradation and downregulating storage lipid accumulation. The sex pheromone of the cotton bollworm Helicoverpa armigera was produced by oxidation of fermented fatty alcohols into corresponding aldehydes. The resulting pheromone was just as efficient and specific for trapping of H. armigera male moths in cotton fields in Greece as a synthetic pheromone mixture. We further demonstrated the production of the main pheromone component of the fall armyworm Spodoptera frugiperda. Our work describes a biotech platform for the production of commercially relevant titres of moth pheromones for pest control by yeast fermentation.Significance statementAgriculture largely relies on insecticides and genetically modified crops for pest control, however alternative solutions are required due to emerging resistance, toxicity and regulatory issues, and consumer preferences. Mating disruption with sex pheromones that act by preventing insect reproduction is considered the most promising and scalable alternative to insecticides. This method is highly efficient and safe for human health and environment. The likelihood of insect resistance development is very low and can be handled by adjusting the pheromone composition. The high cost of chemically synthesized pheromones is the major barrier for the wider adoption of pheromones. A novel method based on yeast fermentation enables the production of insect sex pheromones as a lower cost from renewable feedstocks.
Published: 2020
Full Text: View/download PDF

49. Effects of fatty liver on the size and composition of high‐density lipoprotein cholesterol subpopulations in adolescents with type 2 diabetes mellitus

Author: Aída Xochitl Medina Urrutia, Margarita Torres Tamayo, Pilar Dies Suarez, Juan Reyes Barrera, Juan Gabriel Juárez Rojas, Patricia Medina-Bravo, José Antonio Orozco Morales, and Esteban Jorge Galarza
Subjects: Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Phospholipid, 030209 endocrinology & metabolism, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, High-density lipoprotein, Risk Factors, Internal medicine, Nonalcoholic fatty liver disease, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Child, Triglyceride, business.industry, Cholesterol, Cholesterol, HDL, Fatty liver, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, medicine.disease, Fatty Liver, Cross-Sectional Studies, Endocrinology, Diabetes Mellitus, Type 2, chemistry, Case-Control Studies, Pediatrics, Perinatology and Child Health, Female, lipids (amino acids, peptides, and proteins), business, Lipoprotein
Abstract: BACKGROUND Type 2 diabetes mellitus (T2DM) is an emerging disease in the pediatric population. The association between T2DM and non-alcoholic fatty liver disease (NAFLD) has been described. Recent evidence suggests that sizes and composition of high-density lipoprotein (HDL) may be more important that HDL-C levels in predicting coronary heart disease. There is not data regarding the HDL subclasses distribution and composition in T2DM youths with NAFLD. METHODS This cross-sectional study included 47 adolescents with T2DM and 23 non-diabetic controls of both sexes aged 10 to 18 years. The presence of NAFLD was determined estimated proton density fat fraction (PDFF) by magnetic resonance by spectroscopy. We compared the HDL subclasses distribution (HDL2b, HDL2a, HDL3a HDL3b and HDL3c) and the HDL chemical composition (total protein, triglyceride, phospholipid, cholesteryl esters, and free cholesterol) between the groups of adolescents with T2DM and the control group. RESULTS Patients with T2DM and NAFLD had a significantly lower proportion HDL2b (P = .040) and a higher proportion of HDL3c (P = .035); higher proportion of TG (P = .032) and a lower CE (P = .002) and FC (P
Published: 2020
Full Text: View/download PDF

50. Neurologic recovery in systemic nontraumatic fat embolism syndrome in an elderly patient with hemoglobin SC disease: A case report

Author: Rajat Kapoor, Ayotunde Ositelu, and Samuel Urrutia-Argueta
Subjects: medicine.medical_specialty, fat embolism, lcsh:Medicine, Case Report, Disease, Case Reports, 030204 cardiovascular system & hematology, neurologic recovery, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Bone marrow necrosis, Fat embolism syndrome, medicine, Fat embolism, Elderly patient, lcsh:R5-920, Hematology, Hemoglobin SC Disease, bone marrow necrosis, business.industry, lcsh:R, General Medicine, medicine.disease, Surgery, cerebral fat embolism syndrome, 030220 oncology & carcinogenesis, sickle cell disease, Complication, business, lcsh:Medicine (General)
Abstract: Cerebral fat embolism syndrome is an under‐recognized yet well‐known complication of bone marrow necrosis occurring in patients with sickle cell disease. We highlight a case manifested by multisystem organ failure in an elderly patient who attained neurologic recovery with prompt initiation of hematology consultation, RBC exchange, and supportive measures., Most cases of fat embolism syndrome occur in young patients and are trauma related. A few cases have been described in HbSC disease. Clinicians must have a high index of suspicion in patients with sickle cell disease who develop acute encephalopathy. Urgent/Emergent hematology consultation, RBC exchange, and acute rehabilitation improve outcomes.
Published: 2020

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

1,640 results on '"Urrutia, A."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources